US20210107994A1 - Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii - Google Patents
Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii Download PDFInfo
- Publication number
- US20210107994A1 US20210107994A1 US16/496,089 US201816496089A US2021107994A1 US 20210107994 A1 US20210107994 A1 US 20210107994A1 US 201816496089 A US201816496089 A US 201816496089A US 2021107994 A1 US2021107994 A1 US 2021107994A1
- Authority
- US
- United States
- Prior art keywords
- blood coagulation
- coagulation factor
- polypeptide
- chain
- fix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 114
- 108091007433 antigens Proteins 0.000 title claims abstract description 114
- 102000036639 antigens Human genes 0.000 title claims abstract description 114
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 108010076282 Factor IX Proteins 0.000 title claims description 238
- 108010054218 Factor VIII Proteins 0.000 title claims description 92
- 102000001690 Factor VIII Human genes 0.000 title claims description 92
- 230000005856 abnormality Effects 0.000 title description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 90
- 238000009472 formulation Methods 0.000 claims abstract description 83
- 208000035475 disorder Diseases 0.000 claims abstract description 75
- 230000000694 effects Effects 0.000 claims abstract description 59
- 230000004064 dysfunction Effects 0.000 claims abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 185
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 183
- 229920001184 polypeptide Polymers 0.000 claims description 180
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 163
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 56
- 208000009429 hemophilia B Diseases 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 26
- 108010014173 Factor X Proteins 0.000 claims description 21
- 230000023555 blood coagulation Effects 0.000 claims description 20
- 230000002708 enhancing effect Effects 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 16
- 108010048049 Factor IXa Proteins 0.000 claims description 12
- 230000007547 defect Effects 0.000 claims description 7
- 208000027205 Congenital disease Diseases 0.000 claims description 6
- 206010016077 Factor IX deficiency Diseases 0.000 claims description 6
- 208000037919 acquired disease Diseases 0.000 claims description 6
- 208000009292 Hemophilia A Diseases 0.000 abstract description 29
- 208000032843 Hemorrhage Diseases 0.000 abstract description 28
- 230000000740 bleeding effect Effects 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 26
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract description 18
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract description 18
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract description 14
- 208000011664 congenital factor XI deficiency Diseases 0.000 abstract description 8
- 201000007219 factor XI deficiency Diseases 0.000 abstract description 8
- 230000002947 procoagulating effect Effects 0.000 abstract description 8
- 208000015957 Acquired Von Willebrand disease Diseases 0.000 abstract description 7
- 208000033316 Acquired hemophilia A Diseases 0.000 abstract description 7
- 230000002439 hemostatic effect Effects 0.000 abstract description 6
- 238000002648 combination therapy Methods 0.000 abstract description 4
- 229960004222 factor ix Drugs 0.000 description 140
- 229960000301 factor viii Drugs 0.000 description 57
- 108090000623 proteins and genes Proteins 0.000 description 33
- 241000282414 Homo sapiens Species 0.000 description 32
- 229950006925 emicizumab Drugs 0.000 description 28
- 208000034158 bleeding Diseases 0.000 description 26
- 238000005345 coagulation Methods 0.000 description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 17
- 230000015271 coagulation Effects 0.000 description 17
- 239000013604 expression vector Substances 0.000 description 17
- 238000004904 shortening Methods 0.000 description 17
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 16
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 16
- 239000003114 blood coagulation factor Substances 0.000 description 16
- 230000002265 prevention Effects 0.000 description 16
- 208000031220 Hemophilia Diseases 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 230000002950 deficient Effects 0.000 description 14
- 238000013169 thromboelastometry Methods 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 208000027219 Deficiency disease Diseases 0.000 description 7
- 229940019700 blood coagulation factors Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000011575 calcium Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000003449 preventive effect Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000027276 Von Willebrand disease Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010074860 Factor Xa Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 208000031169 hemorrhagic disease Diseases 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 108010047303 von Willebrand Factor Proteins 0.000 description 4
- 102100036537 von Willebrand factor Human genes 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000013633 acquired hemophilia Diseases 0.000 description 3
- 229940031422 benefix Drugs 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 108700007283 factor IX Fc fusion Proteins 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 238000009256 replacement therapy Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012032 thrombin generation assay Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010080865 Factor XII Proteins 0.000 description 2
- 102000000429 Factor XII Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000031933 Rare hemorrhagic disease Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 208000026578 Severe hemophilia B Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010049769 albutrepenonacog alfa Proteins 0.000 description 2
- 229940071626 alprolix Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960004281 desmopressin Drugs 0.000 description 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010061932 Factor VIIIa Proteins 0.000 description 1
- 108010054265 Factor VIIa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001052793 Homo sapiens GDP-L-fucose synthase Proteins 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- NBFLONVHOGNRHY-YNRDDPJXSA-N PGH2-EA Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(=O)NCCC NBFLONVHOGNRHY-YNRDDPJXSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 229960001354 albutrepenonacog alfa Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- -1 antiseptics Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 108090001015 cancer procoagulant Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical group OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950011162 eftrenonacog alfa Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000050085 human TSTA3 Human genes 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940005850 idelvion Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003163 nonacog alfa Drugs 0.000 description 1
- 229950003943 nonacog gamma Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000020971 positive regulation of blood coagulation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940048932 rixubis Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Definitions
- the present invention relates to pharmaceutical compositions for use in the prevention (prophylaxis) and/or treatment of blood coagulation factor IX (FIX) disorder, which comprise a multispecific antigen-binding molecule that substitutes for the function of (functionally substitute for) blood coagulation factor VIII (FVIII).
- FIX blood coagulation factor IX
- FVIII blood coagulation factor VIII
- FIX disorder is a rare bleeding disorder caused by a congenital defect or dysfunction of FIX (NPL 1).
- FIX disorder is also called hemophilia B.
- FIX is an enzyme precursor, and when the blood coagulation reaction commences, it changes from the precursor to activated blood coagulation factor IX (FIXa) having enzyme activity.
- FIXa forms a blood coagulation factor X-activating complex (tenase complex) together with an activated blood coagulation factor VIII (FVIIIa), and plays an important role in promoting blood coagulation reaction through activation of blood coagulation factor X (FX).
- FVIII disorder is a hemorrhagic disease caused by congenital defect or dysfunction of FVIII, and is also called hemophilia A.
- FIX disorder activated partial thromboplastin time (APTT) is abnormally prolonged, similarly to FVIII disorder.
- FVIII disorder and FIX disorder are distinguished by quantifying FVIII and FIX (FVIII:C and FIX:C for activity quantification, or FVIII:Ag and FIX:Ag for factor antigen quantification).
- Bleeding in FIX disorder is mainly treated by FIX formulations, and regular replacement therapy in which a FIX formulation is administered on a regular basis to prevent bleeding (preventive administration) is also carried out.
- Hemophilia is a hemorrhagic disease caused by congenital defect or dysfunction of FVIII or FIX among the blood coagulation factors.
- the disease caused by FVIII abnormality is called hemophilia A and the disease caused by FIX abnormality is called hemophilia B.
- Severity of the bleeding symptom of hemophilia correlates well with the activity level of the deficient coagulation factor in the blood. Patients with activity of less than 1% are classified as severe, patients with activity of 1% or more and less than 5% are classified as moderate, and patients with activity of 5% or more and less than 40% are classified as mild. Patients with severe symptoms, accounting for approximately half of hemophilia patients, exhibit bleeding symptoms several times a month.
- coagulation factor formulations (hemophilia A: FVIII; hemophilia B: FIX) purified from plasma or prepared by genetic engineering techniques are mainly used. These formulations are used for on-demand administration to stop bleeding when it occurs, or for preventive administration to prevent development of bleeding events (NPLs 1 and 4).
- FVIII formulations have a blood half-life of approximately 12 hours, and they therefore need to be administered as frequently as approximately three times a week for the preventive administration (NPLs 5 and 6).
- the half-life of FIX formulations in blood is 16 hours to 28 hours, and is also reportedly largely different between individuals, ranging from three hours to 38 hours.
- inhibitors may develop in hemophilia patients (NPL 8).
- NPL 8 hemophilia patients
- FVII activate blood coagulation factor VII
- APCC APCC
- Acquired hemophilia in which blood coagulation factors become impaired due to acquired development of autologous neutralizing antibodies against blood coagulation factors, may be a related bleeding disorder (NPLs 10 and 11).
- acquired hemophilia is caused by development of anti-FVIII autoantibodies.
- Bypass formulations and such are administered for bleeding in patients with such acquired bleeding disorders; however, similarly, the problem is that frequent intravenous injections are necessary and there are cases where their hemostatic activity is not enough to fully stop bleeding.
- vWF von Willebrand factor
- bispecific antibodies are being developed as pharmaceutical compositions for prevention and/or treatment of bleeding in hemophilia A (PTLs 1, 2, and 3, and NPLs 13, 14, 15, 16, 17, and 18). Furthermore, application of the bispecific antibodies to prevention and/or treatment of bleeding in acquired hemophilia A and von Willebrand disease, and hemophilia C, which involve dysfunction of FVIII, has also been contemplated (PTLs 1, 2, 3, and 4). In addition, use of the bispecific antibodies in combination with a FIX formulation is also contemplated in the treatment of hemophilia A (PTL 5).
- An objective of the present invention is to provide pharmaceutical compositions for use in the prevention and/or treatment of FIX disorder, which comprise multispecific antigen-binding molecules that substitute for the function of (functionally substitute for) FVIII.
- the present inventors examined the blood/plasma coagulation-promoting action (procoagulant activity) of “multispecific antigen-binding molecules substituting for the function of FVIII (FVIII function-substituting molecules)” by coagulation evaluation methods, ROTEM and APTT, using commercially-available FIX-deficient human plasma and blood/plasma derived from patients with FIX disorder.
- multispecific antigen-binding molecules that functionally substitute for FVIII show procoagul ant activity in blood/plasma derived from FIX disorder patients and in FIX-deficient human plasma. Therefore, multispecific antigen-binding molecules that substitute for the function of FVIII can not only be used as prophylactic (preventive) and/or therapeutic agents against bleeding in hemophilia A, acquired hemophilia A, von Willebrand disease and hemophilia C, which are caused by dysfunction of FVIII, but also as prophylactic and/or therapeutic agents against bleeding in FIX disorder, because of its procoagulant activity.
- the present invention relates to pharmaceutical compositions for use in the prophylaxis (prevention) and/or treatment of FIX disorder, excluding hemophilia A, acquired hemophilia A, von Willebrand disease and hemophilia C, comprising a multispecific antigen-binding molecule that substitutes for the function of FVIII. More specifically the present invention relates to the following:
- IX disorder which comprises a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII;
- the bispecific antibody is:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising the H chain CDR 1, 2, and 3 amino acid sequences of SEQ NOs: 4, 5, and 6 (H chain CDRs of J327), and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 7, 8, and 9 (L chain CDRs of L404);
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15;
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12.
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair
- the first polypeptide consists of an H chain comprising the H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499)
- the second polypeptide consists of an H chain comprising the H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 4, 5, and 6 (H chain CDRs of J327)
- the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain CDR 1, 2, and 3 amino acid sequences of SEQ NOs: 7, 8, and 9 (L chain CDRs of L404);
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15;
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12; [A6] the method of any one of [A1] to [A5], wherein the blood coagulation factor IX disorder is a disease that develops and/or progresses due to a decrease, dysfunction, and/or defect in the activity of blood coagulation factor IX and/or activated blood coagulation factor IX;
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising the H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 4, 5, and 6 (H chain CDRs of J327), and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 7, 8, and 9 (L chain CDRs of L404);
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15;
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12;
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising the H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 4, 5, and 6 (H chain CDRs of J327), and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 7, 8, and 9 (L chain CDRs of L404);
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of art H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12;
- [C6] the use of any one of [C1] to [C5], wherein the blood coagulation factor IX disorder is a disease that develops and/or progresses due to a decrease, dysfunction, and/or defect in the activity of blood coagulation factor IX and/or activated blood coagulation factor IX;
- [C7] the use of any one of [C1] to [C6], wherein the blood coagulation factor IX disorder is a congenital or acquired disease;
- [C8] the use of any one of [C1] to [C7], wherein the blood coagulation factor IX disorder is hemophilia B or blood coagulation factor IX deficiency disease;
- [C9] the use of any one of [C1] to [C8], wherein the medicament is a combination medicament with a blood coagulation factor IX formulation;
- [C10] the use of any one of [C1] to [C8], wherein the medicament is a medicament for enhancing the blood coagulation activity of
- compositions for use in preventing and/or treating FIX disorders other than hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C are provided by the present invention.
- FIG. 1 shows the shortening ratios of blood coagulation (initiation) time according to Ca-triggered Whole blood coagulability test (ROTEM) using blood samples from FIX disorder patients under regular administration therapy.
- ROTEM Whole blood coagulability test
- FIG. 2 shows the ratio of APTT shortening when ACE910 (100 ⁇ g/mL) was added ex vivo to plasma from FIX disorder patients. The abbreviations in the figure are explained below.
- FIG. 3-1 shows evaluation of the ratio of APTT shortening determined from values before and after addition of 100 ⁇ g/mL ACE910, when a FIX formulation (rFIX, BeneFix, Pfizer) at a concentration of 0, 0.01, 0.1, 1, 10, or 100 IU/dL, or an anti-FIX-Gla antibody (anti-FIX Ab) was added to a commercially available FIX-deficient human plasma (FIXd-plasma or sFIXd) and this was subjected to further ex vivo addition of ACE910.
- a FIX formulation rFIX, BeneFix, Pfizer
- an anti-FIX-Gla antibody anti-FIX Ab
- FIG. 3-2 shows the result obtained by further adding an anti-FIX-Gla antibody (aFIXAb) to the FIX-deficient human plasma ex vivo.
- aFIXAb anti-FIX-Gla antibody
- the multispecific antigen-binding molecule that substitutes for the function of FVIII of the present invention can also be referred to as a multispecific antigen-binding molecule having FVIII-like activity.
- the phrase “functionally substitute/substituting for FVIII (substitute/substituting for the function of FVIII)” means that FX activation by FIXa is promoted (FXa generation by FIXa is promoted).
- the phrase “functionally substitute/substituting for FVIII (substitute/substituting for the function of FVIII)” means recognizing FIX and/or FIXa, and FX, and promoting activation of FX by FIXa (promoting FXa generation by FIXa).
- the activity of promoting FXa generation can be evaluated by methods well known in the art, for example using a measurement system comprising FIXa, FX, synthetic substrate S-2222 (synthetic substrate of FXa), and phospholipids.
- evaluations can be carried out according to the methods described in WO 2005/035756, WO 2006/109592, WO 2012/067176, or such.
- Multispecific antigen-binding molecules of the present invention comprise a first antigen-binding site and a second antigen-binding site that can specifically bind to at least two different types of antigens or epitopes. While the first antigen-binding site and the second antigen-binding site are not particularly limited as long as they have an activity to bind to FIX and/or FIXa, and FX, respectively, examples include sites necessary for binding with antigens, such as antibodies, scaffold molecules (antibody-like molecules) or peptides, or fragments containing such sites. Scaffold molecules are molecules that exhibit function by binding to target molecules, and any polypeptide may be used as long as they are conformationally stable polypeptides that can bind to at least one target antigen.
- polypeptides examples include antibody variable regions, fibronectin (WO 2002/032925) protein A domain (WO 1995/001937), LDL receptor A domain (WO 2004/044011, WO 2005/040229), ankyrin (WO 2002/020565), and such, and also molecules described in documents by Nygren et al. (Current Opinion in Structural Biology 1997; 7: 463-469; and Journal of Immunol Methods 2004; 290: 3-28), Binz et al. (Nature Biotech 2005; 23: 1257-1266), and Hosse et al. (Protein Science 2006; 15: 14-27). Furthermore, as mentioned in Curr Opin Mol Ther 2010; 12(4): 487-95 and Drugs 2008; 68(7). 901-12, peptide molecules that can bind to target antigens may be used.
- multispecific antigen-binding molecules are not particularly limited as long as they are molecules that can bind to at least two different types of antigens or epitopes, but examples include polypeptides containing the above-mentioned antigen-binding sites, such as antibodies and scaffold molecules as well as their fragments, and aptamers comprising nucleic acid molecules and peptides, and they may be single molecules or multimers thereof.
- Preferred multispecific antigen-binding molecules include multispecific antibodies that can bind specifically to at least two different antigens.
- Particularly preferred examples of multispecific antibodies of the present invention include bispecific antibodies (BsAb) that can bind specifically to two different antigens (they may also be called dual specific antibodies).
- common L chain refers to an L chain that respectively forms a pair with two or more different H chains, and can show binding ability to each antigen.
- different H chain(s) preferably refers to H chains of antibodies against different antigens, but is not limited thereto, and also refers to H chains whose amino acid sequences are different from each other.
- Commonly shared L chain can be obtained, for example, according to the method described in WO 2006/109592.
- multispecific antigen-binding molecules, multispecific antibodies, or bispecific antibodies of the present invention respectively have a plurality of antibody L chains
- those antibody L chains may be different from one another or they may be a common L chain.
- a multispecific antigen-binding molecule is a multispecific antigen-binding molecule that recognizes FIX and/or FIXa, and FX, and functionally substitutes for FVIII; preferably a multispecific antibody that recognizes FIX and/or FIXa, and FX, and functionally substitutes for FVIII; and more preferably a bispecific antibody that recognizes FIX and/or FIXa, and FX, and functionally substitutes for FVIII.
- the antigen-binding molecule or the antibody of the present invention preferably comprises variable regions in an anti-FIXa antibody and variable regions in an anti-FX antibody.
- the multispecific antigen-binding molecule, multispecific antibody, or bispecific antibody comprises a first polypeptide and a third polypeptide comprising an antigen-binding site that recognizes FIX and/or FIXa, and a second polypeptide and a fourth polypeptide comprising an antigen-binding site that recognizes FX.
- the first polypeptide and the third polypeptide, and the second polypeptide and the fourth polypeptide include the antigen-binding site of an antibody H chain and the antigen-binding site of an antibody L chain.
- the first polypeptide and the third polypeptide contain the antigen-binding site of an H chain and an L chain, respectively, of an antibody against FIX or FIXa
- the second polypeptide and the fourth polypeptide contain the antigen-binding site of an H chain and an L chain, respectively, of an antibody against FX.
- the antibody L chain antigen-binding sites contained in the first polypeptide and the third polypeptide, and in the second polypeptide and the fourth polypeptide may be the antigen-binding site of a common L chain.
- the polypeptides comprising an antibody L chain antigen-binding site preferably contain the sequence of the whole or a part of the L chain of an antibody binding to FIX, FIXa and/or FX.
- a preferred embodiment of multispecific antigen-binding molecule that functionally substitutes for FVIII in the present invention includes, for example, a bispecific antibody that recognizes FIX and/or FIXa, and FX.
- a bispecific antibody that recognizes FIX and/or FIXa, and FX.
- Such an antibody can be obtained according to methods described, for example, in WO 2005/035756, WO 2006/109592, and WO 2012/067176.
- the bispecific antibody of the present invention includes antibodies described in these documents.
- a preferred bispecific antibody includes the antibody (ACE910: Emicizumab) below, which is a bispecific antibody described in a patent document (WO 2012/067176):
- a bispecific antibody in which a first polypeptide forms a pair with a third polypeptide and a second polypeptide forms a pair with a fourth polypeptide, wherein the first polypeptide consists of an H chain comprising the amino acid sequences of H chain CDR 1, 2, and 3 of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising the amino acid sequences of H chain CDR 1, 2, and 3 of SEQ ID NOs: 4, 5, and 6 (H chain CDRs of J327), and the third and fourth polypeptides consist of a common L chain comprising the amino acid sequences of L chain CDR 1, 2, and 3 of SEQ ID NOs: 7, 8, and 9.
- the antibody is a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15.
- the antibody is a bispecific antibody (Q499-z121/J327-z119/L404-k) in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12.
- Amino acids contained in the amino acid sequences described in the present invention may be post-translationally modified (for example, the modification of an N-terminal glutamine into a pyroglutamic acid by pyroglutamylation is well-known to those skilled in the art). Naturally, antibodies with such post-translationally modified amino acids are included in the antibodies used in the present invention.
- the term “recognize(s)” in the phrase “an antibody which recognizes antigen A”, the term “bind(s)” in the phrase “an antibody which binds to antigen A”, and the term “specifically bind(s)” in the phrase “an antibody which specifically binds to antigen A” may be used interchangeably in a broad sense.
- Polypeptides in the present invention normally refer to proteins and peptides having a length of approximately ten amino acids or longer. Generally, they are biologically derived polypeptides, but are not particularly limited to such polypeptides, and may be, for example, polypeptides comprising an artificially designed sequence. Furthermore, they may be any native polypeptides, or synthetic polypeptides, recombinant polypeptides, or such. Additionally, the fragments of the above-mentioned polypeptides are also included in the polypeptides of the present invention.
- antibody is used in the broadest sense, and may be monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (for example, bispecific antibodies), antibody derivatives, and modified antibody products (Miller K et al J Immunol. 2003, 170(9), 4854-61) as long as they display a desired biological activity.
- the antibodies may be mouse antibodies, human antibodies, humanized antibodies, chimeric antibodies, or those derived from another species, or they may be artificially synthesized antibodies.
- the antibodies disclosed herein can be of any type (for example, IgG, IgE, IgM, IgD, and IgA), class (for example, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecules.
- the immunoglobulins can be derived from any species (for example, human, mouse, or rabbit).
- the terms “antibody”, “immune globulin” and “immunoglobulin” are used interchangeably in a broad sense.
- antibody derivative includes a portion of an antibody, preferably an antibody variable domain, or at least an antigen-binding region of an antibody.
- Antibody derivatives include, for example, Fab, Fab′, F(ab′)2, Fv fragments, linear antibodies, and single-chain antibodies (scFv), sc(Fv) 2 , Fab 3 , domain antibodies (dAb) (WO 2004/058821, WO 2003/002609), diabodies, triabodies, tetrabodies, minibodies, and multispecific antibodies formed from antibody derivatives, but are not limited thereto.
- Fab is constructed from a single light chain and the CH1 domain and variable region of a single heavy chain.
- Fv is the smallest antibody derivative, and includes a complete antigen-recognizing region and an antigen-binding region.
- the antibody derivative may be, for example, a fusion between an IgG antibody and Fc.
- Example 2 in U.S. Pat. No. 5,641,870 specification; Zapata Get at. Protein Eng. 1995, 8(10), 1057-1062; Olafsen T et al. Protein Eng. Design & Sel. 2004, 17(4): 315-323; Holliger P et al. Nat. Biotechnol. 2005, 23(9): 1126-36; Fischer N et al. Pathobiology. 2007, 74(1): 3-14; Shen J et al, J Immunol Methods. 2007, 318, 65-74; and Wu et al. Nat Biotechnol. 2007, 25(11), 1290-7.
- Diabodies are bivalent low-molecular weight antibodies (minibodies) constructed by gene fusion (Holliger, P. et al., Proc. Natl. Acad. Sci. USA 1993; 90: 6444-6448; EP 404,097; WO 93/11161), Diabodies are dimers consisting of two polypeptide chains, in which each polypeptide chain comprises an L chain variable region (VL) and an H chain variable region (VH) linked with a linker short enough to prevent association of these two domains within the same chain, for example, a linker of preferably 2 to 12 amino acids, more preferably 3 to 10 amino acids, particularly about 5 amino acids.
- the polypeptide chain form a dimer since the linker between the VL and VH encoded on the same polypeptide is too short to form a single chain variable region fragment. Therefore, diabodies comprise two antigen-binding sites.
- a single-chain antibody or an scFv antibody fragment comprises the VH and VL regions of an antibody, and these regions exist in a single polypeptide chain.
- an Fv polypeptide further comprises a polypeptide linker between the VH and VL regions, and this enables an scFv to form a structure necessary for antigen binding (for a review on scFvs, see Pluckthun “The Pharmacology of Monoclonal Antibodies” Vol. 113 (Rosenburg and Moore ed. (Springer Verlag, New York) pp. 269-315, 1994).
- linkers are not particularly limited so long as they do not inhibit the expression of the antibody variable regions linked at their ends.
- Bispecific antibodies may be produced by chemically crosslinking Fab′s.
- Bispecific F(ab′) 2 can be produced, for example, by preparing Fab′ from an antibody, using it to produce a maleimidized Fab′ with ortho-phenylenedi-maleimide (o-PDM), and then reacting this with Fab′ prepared from another antibody to crosslink Fab′s derived from different antibodies (Keler T et al. Cancer Research 1997, 57: 4008-4014).
- o-PDM ortho-phenylenedi-maleimide
- the method of chemically linking an Fab′-thionitrobenzoic acid (TNB) derivative and an antibody fragment such as Fab′-thiol (SH) is also known (Brennan M et al. Science 1985; 229: 81-83),
- a leucine zipper derived from Fos and Jun may also be used. Preferential formation of heterodimers by Fos and Jun is utilized, even though they also form homodimers.
- Fab′ to which Fos leucine zipper is added, and another Fab′ to which Jun leucine zipper is added are expressed and prepared. Monomeric Fab′-Fos and Fab′-Jun reduced under mild conditions are mixed and reacted to form bispecific F(ab′) 2 (Kostelny S A et at. J. of Immunology, 1992, 148: 1547-53). This method can be applied not only to Fab′s but also to scFvs, Fvs, and such.
- bispecific antibodies including sc(Fv) 2 such as IgG-scFv (Protein Eng Des Sel. 2010; 23(4): 221-8) and BiTE (Drug Discov Today 2005; 15; 10(18): 1237-44), DVD-Ig (Nat Biotechnol. 2007; 25(11): 1290-7. Epub 2007 Oct 14; and MAbs 2009; 1(4): 339-47. Epub 2009 Jul.
- a bispecific antibody may also be produced using a diabody.
- a bispecific diabody is a heterodimer of two cross-over scFv fragments. More specifically, it is produced by forming a heterodimer using VH(A)-VL(B) and VH(B)-VL(A) prepared by linking VHs and VLs derived front two kinds of antibodies, A and B, using a relatively short linker of about 5 residues (Holliger P et al. Proc Natl. Acad. Sci. USA 1993; 90: 6444-6448).
- the desired structure can be achieved by linking the two scFvs with a flexible and relatively long linker comprising about 15 residues (single chain diabody: Kipriyanov S M et at. J. of Molecular Biology 1999; 293: 41-56), and conducting appropriate amino acid substitutions (knobs-into-holes: Zhu Z et al. Protein Science 1997; 6: 781-788; VH/VL interface engineering: Igawa T et al. Protein Eng Des Sel 2010; 8: 667-77).
- An sc(Fv) 2 that can be produced by linking two types of scFvs with a flexible and relatively long linker, comprising about 15 residues, may also be a bispecific antibody (Mallender W D et al. J. of Biological Chemistry 1994; 269: 199-206).
- modified antibody products may include antibodies linked to various molecules such as polyethylene glycol (PEG).
- Antibodies of the present invention include such modified antibody products.
- the substance to be linked is not limited in the modified antibody products of the present invention.
- chemical modifications can be made to the obtained antibodies. Such methods are already established in this field.
- Bispecific antibodies refer to antibodies having variable regions that recognize different epitopes, where the regions are within the same antibody molecule. Bispecific antibodies may be antibodies that recognize two or more different antigens or antibodies that recognize two or more different epitopes on the same antigen. Bispecific antibodies may include not only whole antibodies but antibody derivatives. Antibodies of the present invention also include bispecific antibodies. Herein, anti-FIXa/FX bispecific antibody and bispecific antibody that recognizes FIXa and FX are used synonymously.
- Recombinant antibodies produced by using genetic engineering techniques can be used as the antibodies.
- Recombinant antibodies can be obtained by cloning DNAs encoding the antibodies from hybridomas or antibody-producing cells such as sensitized lymphocytes that produce antibodies, inserting them into vectors, and then introducing them into hosts (host cells) to produce the antibodies.
- the antibodies include human antibodies, mouse antibodies, and rat antibodies, and their origin is not limited. They may also be genetically modified antibodies such as chimeric antibodies and humanized antibodies.
- transgenic animals carrying the entire repertoire of human antibody genes can be immunized with antigens of interest to obtain human antibodies of interest (see International Publication WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).
- chimeric antibodies comprise H chain and L chain variable regions of an immunized animal antibody, and H chain and L chain constant regions of a human antibody.
- Chimeric antibodies can be obtained by linking DNAs encoding the variable regions of the antibody derived from the immunized animal, with DNAs encoding the constant regions of a human antibody, inserting this into an expression vector, and then introducing it into host to produce the antibodies.
- Humanized antibodies are modified antibodies that are also referred to as reshaped human antibodies.
- a humanized antibody is constructed by transferring the complementarity determining regions (CDRs) of an antibody derived from an immunized animal to the CDRs of a human antibody.
- CDRs complementarity determining regions
- Conventional genetic recombination techniques for such purposes are known (see European Patent Application Publication No. EP 239400; international Publication No. WO 96/02576; Sato K et al., Cancer Research 1993, 53: 851-856; international Publication No. WO 99/51743).
- bispecific antibodies are not limited to those of the IgG type, for example, IgG-type bispecific antibodies can be secreted from a hybrid hybridoma (quadroma) produced by fusing two types of hybridomas that produce IgG antibodies (Milstein C. et al, Nature 1983, 305: 537-540). They can also be secreted by introducing the L chain and H chain genes constituting the two types of IgGs of interest, a total of four types of genes, into cells to co-express the genes.
- IgGs having a heterogeneous combination of H chains can be preferentially secreted (Ridgway J B et al. Protein Engineering 1996, 9: 617-621; Merchant A M et al. Nature Biotechnology 1998, 16: 677-681; WO 2006/106905; Davis J H et al. Protein Eng Des Sel. 2010, 4: 195-202).
- the antibodies of the present invention may be antibodies comprising common L chains.
- Bispecific IgGs can be efficiently expressed by introducing the gene of the common L chain and both H chains into cells.
- Antibodies of the present invention can be produced by methods known to those skilled in the art. Specifically, DNA encoding the antibody of interest is inserted into an expression vector. Insertion into an expression vector is carried out such that the expression will take place under the control of expression regulatory regions such as enhancers and promoters. Next, host cells are transformed using this expression vector to express the antibodies. Appropriate combinations of the host and expression vector can be used in this step.
- vectors examples include M13 series vectors, pUC series vectors, pBR322, pBluescript, and pCR-Script.
- pGEM-T, pDIRECT, or pT7 can also be used for the purpose of cDNA subcloning and excision.
- expression vectors are useful for using the vectors for the purpose of producing the antibody.
- the expression vectors indispensably have a promoter that permits efficient expression in E. coli , for example, lacZ promoter (Ward et al., Nature (1989) 341, 544-546; and FASEB J (1992) 6, 2422-2427), araB promoter (Better et al., Science (1988) 240, 1041-1043), or T7 promoter.
- promoter that permits efficient expression in E. coli
- lacZ promoter Ward et al., Nature (1989) 341, 544-546; and FASEB J (1992) 6, 2422-2427
- araB promoter Better et al., Science (1988) 240, 1041-1043
- T7 promoter examples include the vectors mentioned above as well as pGEX-5X-1 (manufactured by Pharmacia).
- QIAexpress system manufactured by QIAGEN
- pEGFP pEGFP
- the vectors may contain a signal sequence for polypeptide secretion.
- pelB signal sequence Lei, S. P. et al., J. Bacteriol. (1987) 169, 4397) can be used as the signal sequence for polypeptide secretion.
- the vectors can be transferred to the host cells using, for example, calcium chloride methods or electroporation methods.
- examples of the vectors for producing the antibody of the present invention include mammal-derived expression vectors (e.g., pcDNA3 (manufactured by Invitrogen Corp.), pEGF-BOS (Nucleic Acids. Res.
- insect cell-derived expression vectors e.g., “Bac-to-BAC baculovairus expression system” (manufactured by GIBCO BRL), and pBacPAK8)
- plant-derived expression vectors e.g., pMH1 and PMH2
- animal virus-derived expression vectors e.g., pHSV, pMV, and pAdexLcw
- retrovirus-derived expression vectors e.g., pZIPneo
- yeast-derived expression vectors e.g., “Pichia Expression Kit” (manufactured by Invitrogen Corp.), pNV11, and SP-Q01
- Bacillus subtilis -derived expression vectors e.g., pPL608 and pKTH50.
- the vectors indispensably have a promoter necessary for intracellular expression, for example, SV40 promoter (Mulligan et al., Nature (1979) 277, 108), MMTV-LTR promoter, EF1 ⁇ promoter (Mizushima et al., Nucleic Acids Res (1990) 18, 5322), CAG promoter (Gene (1991) 108, 193), or CMV promoter and, more preferably, have a gene for screening for transformed cells (e.g., a drug resistance gene that can work as a marker by a drug (neomycin, G418, etc.)).
- a promoter necessary for intracellular expression for example, SV40 promoter (Mulligan et al., Nature (1979) 277, 108), MMTV-LTR promoter, EF1 ⁇ promoter (Mizushima et al., Nucleic Acids Res (1990) 18, 5322), CAG promoter (Gene (1991) 108,
- An exemplary method intended to stably express the gene and increase the number of intracellular gene copies involves transfecting CHO cells deficient in nucleic acid synthesis pathway with vectors having a DHFR gene serving as a complement thereto (e.g., pCHOI) and using methotrexate (MTX) in the gene amplification.
- An exemplary method intended to transiently express the gene involves using COS cells having a gene which expresses an SV40 T antigen on their chromosomes to transform the cells with vectors having a replication origin of SV40 (pcD, etc).
- a replication origin derived from polyomavirus, adenovirus, bovine papillomavirus (BPV), or the like may be used.
- the expression vectors for increasing the number of gene copies in a host cell system can additionally contain a selection marker such as an aminoglycoside transferase (APH) gene, a thymidine kinase (TK) gene, an E. coli xanthine guanine phosphoribosyltransferase (Ecogpt) gene, or a dihydrofolate reductase (dhfr) gene.
- APH aminoglycoside transferase
- TK thymidine kinase
- Eugpt E. coli xanthine guanine phosphoribosyltransferase
- dhfr dihydrofolate reductase
- the antibodies of the present invention obtained by the methods described above can be isolated from inside host cells or from outside of the cells (the medium, or such), and purified to practically pure and homogeneous antibodies.
- the antibodies can be separated and purified by methods routinely used for separating and purifying antibodies, and the type of method is not limited.
- the antibodies can be separated and purified by appropriately selecting and combining column chromatography, filtration, ultrafiltration, salting-out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectrofocusing, dialysis, recrystallization, and such.
- the chromatographies include, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et ai., Cold Spring Harbor Laboratory Press, 1996).
- the chromatographic methods described above can be conducted using liquid-chromatography, for example, HPLC and FPLC.
- Columns used for affinity chromatography include protein A columns and protein G columns.
- Columns using protein A include, for example, Hyper D, POROS, and Sepharose FF (GE Amersham Biosciences).
- the present invention includes antibodies that are highly purified using these purification methods.
- compositions used for therapeutic or preventive purposes of the present invention can be prepared by mixing, if necessary, with suitable pharmaceutically acceptable carriers, vehicles, and such, and then made into lyophilized formulations or solution formulations.
- suitable pharmaceutically acceptable carries and vehicles include sterilized water, physiological saline, stabilizers, excipients, antioxidants (such as ascorbic acid), buffers (such as phosphate, citrate, histidine, and other organic acids), antiseptics, surfactants (such as PEG and Tween), chelating agents (such as EDTA), and binders.
- They may also comprise other low-molecular-weight polypeptides, proteins such as serum albumin, gelatin, and immunoglobulins, amino acids such as glycine, glutamine, asparagine, glutamic acid, asparagic acid, methionine, arginine, and lysine, sugars and carbohydrates such as polysaccharides and monosaccharides, and sugar alcohols such as mannitol and sorbitol.
- proteins such as serum albumin, gelatin, and immunoglobulins
- amino acids such as glycine, glutamine, asparagine, glutamic acid, asparagic acid, methionine, arginine, and lysine
- sugars and carbohydrates such as polysaccharides and monosaccharides
- sugar alcohols such as mannitol and sorbitol.
- physiological saline and isotonic solutions comprising glucose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride may be used, and if necessary, in combination with appropriate solubilizers such as alcohol (for example, ethanol), polyalcohols (such as propylene glycol and PEG), and nonionic surfactants (such as polysorbate 80, polysorbate 20, poloxamer 188, and HCO-50).
- solubilizers such as alcohol (for example, ethanol), polyalcohols (such as propylene glycol and PEG), and nonionic surfactants (such as polysorbate 80, polysorbate 20, poloxamer 188, and HCO-50).
- solubilizers such as alcohol (for example, ethanol), polyalcohols (such as propylene glycol and PEG), and nonionic surfactants (such as polysorbate 80, polysorbate 20, poloxamer 188, and HCO-50).
- compositions of the present invention can be administered to patients via any suitable route.
- patients can be treated with bolus or continuous infusion over a period of time via an intravenous, intramuscular, intraperitoneal, intracerebral, transdermal, subcutaneous, intraarticular, sublingual, intrasynovial, oral, inhalation, topical or external route.
- Intravenous administration or subcutaneous administration is preferred.
- Patients in the present application include human patients and non-human animal patients.
- the term “patient” is used interchangeably with “subject” and “individual”.
- the dosage is, for example, 0.001 mg/kg to 1000 mg/kg in the case of the above-mentioned bispecific antibody.
- the administration interval is at least one day or longer in the case of the above-mentioned bispecific antibody.
- ROTEM Rotation thromboelastometry
- APTT activated partial thromboplastin time
- CWA clot waveform analysis
- TGA thrombin generation assay
- ROTEM is an examination method that can comprehensively evaluate the coagulability and coagulation process of blood by monitoring a thrombelastograph (change in elasticity of clotted blood). It is generally used for analyzing causes of bleeding and for determining effects of therapeutic agents.
- a reaction-initiating reagent such as a Ca trigger is added to a test blood, and clotting time (CT), clot formation time (CFT), and such are measured as evaluation parameters.
- APTT has long been widely used as a method for monitoring the drug efficacy of FVIII formulations.
- APTT is a method in which an APTT reagent is added to test plasma, after which CaCl 2 is added, and the time for fibrinogen to be converted into insoluble fibrin, that is, the time until coagulation starts, is measured.
- CWA is a test in which the amount of fibrin generated as the coagulation reaction progresses is measured as optical (e.g., absorbance) changes over time.
- optical e.g., absorbance
- the APTT reagent (Thromb Haemost 2002; 87 (3): 436-41, J Thromb Haemost 2006; 4 (2): 377-84)
- a reagent with a mixed solution of a low concentration of tissue factor (TF) and a blood coagulation factor XII (FXII) activator (ellagic acid)
- J Thromb Haemost 2014; 12 (3): 355-62 J Thromb Haemost 2014; 12 (3): 355-62
- the clot waveform is a waveform representing a temporal change in optical information (absorbance) related to the amount of light.
- the clot waveform is differentiated (first differentiation) to calculate the coagulation velocity, and the maximum coagulation velocity is used as a parameter.
- the coagulation velocity is differentiated (secondary differentiation) to calculate coagulation acceleration, and the maximum coagulation acceleration is used as a parameter (Haemophilia 2008; 14: 83-92, J Thromb Haemost 2014; 12 (3): 355-62).
- TGA is an assay in which the amount of thrombin generated as the coagulation reaction progresses is measured as enzymatic activity over time using a fluorescent substrate for thrombin (Haemophilia 2008; 14 (suppl. 3): 83-92).
- compositions used for the prevention and/or treatment of an FIX disorder which comprise a multispecific antigen-binding molecule that substitutes for the function of FVIII, are provided.
- FIX disorders are rare hemorrhagic diseases caused by a congenital defect or dysfunction of FIX, and include, for example, hemophilia B and FIX deficiency disease.
- the decreased activity or defect of FIX includes, for example, those from congenital and/or acquired causes, but is not limited thereto.
- the degree of decrease in FIX activity in patients compared to normal subjects is preferably less than 40% (for example, less than 40%, less than 30%, less than 20%, less than 10%), more preferably less than 10% (for example, less than 10%, less than 9%, or less than 8%, less than 7%, or less than 6%), even more preferably less than 5% (e.g., less than 5%, less than 4%, less than 3%, or less than 2%), particularly preferably less than 1%, but is not limited thereto.
- hemophilia B patients or patients with FIX deficiency disease include patients with or without inhibitors (autoantibodies against FIX), patients with a decrease or a complete lack of FIX level, and patients with a decrease or a complete lack of FIX activity, but are not particularly limited thereto.
- hemophilia B patients or FIX deficiency disease patients are severe hemophilia B patients or severe FIX deficiency disease patients with a trace FIX activity of less than 1.0 IU/dL. In one aspect, hemophilia B patients or FIX deficiency disease patients are hemophilia B patients or FIX deficiency disease patients who do not carry inhibitors.
- hemophilia B and “FIX deficiency disease” are used interchangeably in a broad sense.
- the present invention provides pharmaceutical compositions for use in preventing and/or treating blood coagulation factor IX disorder, which comprise a multispecific antigen-binding molecule that functionally substitutes for FVIII, wherein the compositions are for combined use with blood coagulation factor IX formulations (FIX formulations).
- these pharmaceutical agents may be administered simultaneously or consecutively, or one may be administered first and then the other may be administered after a period of time.
- the present invention provides pharmaceutical compositions for use in preventing and/or treating blood coagulation factor IX disorder, which comprise a multispecific antigen-binding molecule that functionally substitutes for FVIII, wherein the composition is for enhancing the blood coagulation activity of FIX formulations.
- the present invention provides combination medicaments for use in preventing and/or treating blood coagulation factor IX disorder, which are a combination of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII and a FIX formulation.
- the present invention provides methods for enhancing the blood coagulation activity of FIX formulations in patients with a blood coagulation factor IX disorder, using a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII.
- enhancing blood coagulation activity refers to, for example, shortening of APTT by administering the multispecific antigen-binding molecule by at least one second, preferably by at least three seconds or five seconds, and more preferably by at least ten seconds, compared to that before administering the multispecific antigen-binding molecule.
- the present invention provides blood coagulation factor IX formulations for combined use with the pharmaceutical composition for use in preventing and/or treating blood coagulation factor IX disorder, which comprises a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII.
- the present invention provides blood coagulation factor IX formulations for enhancing the FVIII function-substituting activity of the pharmaceutical compositions for use in preventing and/or treating blood coagulation factor IX disorder, which comprise a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII.
- the present invention provides methods for enhancing the FVIII function-substituting activity of multispecific antigen-binding molecules that functionally substitute for blood coagulation factor VIII in patients with blood coagulation factor IX disorder, using a blood coagulation factor IX formulation.
- the FIX formulation may be any pharmaceutical composition comprising FIX regardless of the origin and molecular form of FIX, and includes Christmassin M, Novact M, PPSB-HT, BeneFIX (nonacog alfa), Rixubis (nonacog gamma), Alprolix (eftrenonacog alfa), and Idelvion (albutrepenonacog alfa), but is not particularly limited thereto.
- FIX is not limited to human-derived FIX, and may be FIX derived from humans, bovines, pigs, dogs, cats, or mice/rats.
- FIX is a human FIX, which refers to a human FIX consisting of 415 amino acid residues, which is formed by removing the N-terminal signal sequence and the pro-peptide region consisting of 46 amino acids from the immature human FIX consisting of 461 amino acid residues (SEQ ID NO: 16) (see for example, UniProtKB/Swiss-Prot Accession P00740-1). Human FIX is shown by positions 47 to 461 of SEQ ID NO: 16.
- FIX includes any form of FIX which has the typical features of FIX.
- FIX contains a GLA domain (a domain containing ⁇ -carboxyglutamate residues), two EGF domains (human EGF homology domains), an activation peptide domain, and a C-terminal protease domain.
- GLA domain a domain containing ⁇ -carboxyglutamate residues
- EGF domains human EGF homology domains
- an activation peptide domain a C-terminal protease domain.
- FIX is not necessarily limited to FIX containing the above, and it may contain domains known in this technical field that are synonymous to these domains, or partially-deleted fragments thereof.
- FIX or sequence variants thereof are not limited to the following, but they have been cloned as described in U.S. Pat. Nos.
- FIX variants for example, FIX into which amino acid sequence mutations are artificially introduced
- modified forms of FIX for example, PEGylated FIX
- FIX is simply mentioned in the present application it includes its sequence variants, FIX variants, and modified forms FIX, unless specifically noted otherwise.
- embodiments represented by the expression “comprising . . . ” may include embodiments represented by the expression “essentially consisting of . . . ” and embodiments represented by the expression “consisting of . . . ”.
- the blood/plasma procoagulant activity of a multispecific antigen-binding molecule that functionally substitutes for FVIII was examined using blood or plasma from FIX disorders other than hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C. More specifically, the blood/plasma procoagulant activity of ACE910 (Emicizumab), which is the bispecific antibody described in a patent document (WO 2012/067176) and is one of the aforementioned multispecific antigen-binding molecules, was examined by each of the coagulation evaluation methods, ROTEM and APTT, using blood/plasma derived from hemophilia B patients and a commercially-available FIX-deficient human plasma (George King Bio-Medical).
- ACE910 Emicizumab
- ACE910 which is an Anti-FIXa/FX Bispecific Antibody that Substitutes for FVIII Function
- ACE910 was obtained by the methods described in WO 2005/035756, WO 2006/109592, and WO 2012/067176.
- the bispecific antibody was expressed by incorporating the antibody genes into animal cell expression vectors and transfecting them into CHO cells, The bispecific antibody contained in the cell culture supernatant was then purified.
- the FVIII function-substituting activity of the thus purified hispecific antibody was measured by the enzyme assay shown below.
- 1 nM human FIXa Enzyme Research Laboratories
- 140 nM human FX Enzyme Research Laboratories
- 20 ⁇ M phospholipids (10% phosphatidylserine, 60% phosphatidylcholine, 30% phosphatidylethanolamine
- the hispecific antibody were mixed with Tris-buffered saline solution containing 5 mM CaCl 2 and 0.1% bovine serum albumin, and incubated for 2 minutes to cause the FX activation reaction by FIXa to proceed. This reaction was terminated by adding EDTA.
- FXa-specific chromogenic substrate solution S-2222 (CHROMOGENIX) was added, and the change in absorbance at 405 nm was measured using SpectraMax 340PC384 (Molecular Devices).
- a calibration curve was prepared from the change in absorbance by human FXa (Enzyme Research Laboratories) at known concentrations, and the FXa production-promoting activity of the bispecific antibody was evaluated.
- ROTEM measurements were performed according to a usual method using the ROTEM delta measurement device (Tem International GmbH).
- a Ca trigger a calcium solution star-tem reagent (Ref No. 503-01, Tem International GmbH) was used.
- Thrombocheck APTT-SLA (Sysmex) was used as the APTT reagent. 50 ⁇ L of the APTT reagent was added to 50 ⁇ L of FIX disorder patient-derived plasma or FIX-deficient human plasma containing ACE910 and/or anti-FIX-Gla antibody (Thromb Res 2000; 100: 73-79). After incubation at 37° C. for five minutes, 50 ⁇ L of 0.02. mol/L calcium chloride solution was added to initiate the coagulation reaction, and APTT was measured according to a conventional method with an automated blood coagulation measurement device (CS-2000i, Svsmex).
- CS-2000i automated blood coagulation measurement device
- Percentage shortening of APTT [(1—APTT after addition of ACE910/APTT before addition of ACE910) ⁇ 100] was determined using samples prepared by adding ACE910 to plasma derived from FIX disorder patients or FIX-deficient human plasma.
- ACE910 100 ⁇ g/mL was added ex vivo in the plasma of 10 cases of FIX disorder patients, no APTT shortening effect was observed in one FIX inhibitor-positive case, with a shortening ratio of ⁇ 6% (APTT ratio of 1.06). However, in all of the remaining nine cases (FIX:C range of 0.9 IU/dL to 6.4 IU/dL). ACE910 was effective in shortening APTT, with a median shortening ratio of 39% (ranging from 35% to 45%) (APTT' ratio of 0.55 to 0.65) ( FIG. 2 ).
- FIX formulation (BeneFix, Pfizer) was added at concentrations of 0, 0.01, 0.1, 1, 10, and 100 IU/dL to commercially-available FIX-deficient human plasma, and ACE910 was further added ex viva. The percentage by which the APTT was shortened after addition of 100 ⁇ g/mL
- ACE910 was evaluated. The result showed that the percentage APTT shortening was 7%, 11%, 19%, 26%, 30%, and 33% according to the respective concentrations of the FIX formulation ( FIG. 3-1 ).
- the APTT shortening effect of ACE910 was FIX concentration-dependent, and when the FIX concentration was from 1 IU/dL to 100 IU/dL, the level of change in the shortening ratio was nearly stable (26% to 33%).
- FIX is essential for ACE910 to express its effect, and the effect is exerted in the presence of even a trace amount of FIX (at the level of 0.01 IU/dL).
- a calibration curve for APTT shortening by changes in the concentration of FIX was prepared by adding only the FIX formulation at varying concentrations to FIX-deficient human plasma, and this calibration curve was used to convert the APTT obtained with addition of ACE910 into FIX:C.
- the present invention provides methods of using multispecific antigen-binding molecules that functionally substitute for FVIII as a prevention method and/or a treatment method for onset and/or progress of bleeding, diseases accompanying bleeding, or diseases caused by bleeding in FIX disorders other than hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C. It is considered that multispecific antigen-binding molecules that functionally substitute for FVIII can be used not only as prevention methods and/or treating methods for bleeding in hemophilia A, acquired hemophilia. A, von Willebrand disease, and hemophilia C which are caused by FVIII dysfunction, but also as prevention methods and/or treating methods for bleeding in other FIX disorders, because of its procoagulant activity.
- the need of repeated intravenous administration of a FIX formulation leads to the problem of difficulty in securing vascular access, and is very burdensome to the patients and care givers particularly in pediatric cases.
- the antibodies which are multispecific antigen-binding molecules that functionally substitute for FVIII have been developed as a formulation for subcutaneous administration, and are expected to reduce the burden of administration compared to FIX formulations which require repeated intravenous administration. Therefore, the present invention may be promising as a prophylactic agent and/or therapeutic agent for FIX disorders.
- combined use of a multispecific antigen-binding molecule that functionally substitutes for VIII and a FIX formulation can enhance the effect of the FIX formulation, and this may be promising as a combination therapy which shows stable hemostatic effects.
Abstract
Description
- The present invention relates to pharmaceutical compositions for use in the prevention (prophylaxis) and/or treatment of blood coagulation factor IX (FIX) disorder, which comprise a multispecific antigen-binding molecule that substitutes for the function of (functionally substitute for) blood coagulation factor VIII (FVIII).
- FIX disorder is a rare bleeding disorder caused by a congenital defect or dysfunction of FIX (NPL 1). FIX disorder is also called hemophilia B. FIX is an enzyme precursor, and when the blood coagulation reaction commences, it changes from the precursor to activated blood coagulation factor IX (FIXa) having enzyme activity. FIXa forms a blood coagulation factor X-activating complex (tenase complex) together with an activated blood coagulation factor VIII (FVIIIa), and plays an important role in promoting blood coagulation reaction through activation of blood coagulation factor X (FX). Similarly, FVIII disorder is a hemorrhagic disease caused by congenital defect or dysfunction of FVIII, and is also called hemophilia A. In FIX disorder, activated partial thromboplastin time (APTT) is abnormally prolonged, similarly to FVIII disorder. FVIII disorder and FIX disorder are distinguished by quantifying FVIII and FIX (FVIII:C and FIX:C for activity quantification, or FVIII:Ag and FIX:Ag for factor antigen quantification). Bleeding in FIX disorder is mainly treated by FIX formulations, and regular replacement therapy in which a FIX formulation is administered on a regular basis to prevent bleeding (preventive administration) is also carried out. At present, the most commonly used regular replacement therapy protocol for FIX disorder (hemophilia B) is intravenous administration of 25 IU/kg to 40 IU/kg FIX formulation twice a week. However, many different protocols are performed even within the same country, and studying an optimal protocol is a future issue (NPL 1). Furthermore, recently in Japan, FIX formulations with prolonged half-life have been developed, and regular replacement therapy in which intravenous administration is carried out at 50 IU/kg once a week or at 100 IU/kg once every ten days has also become available (NPL 2). However, repeated intravenous administration has the problem of difficulty in securing vascular access, and is very burdensome to the patients and care givers particularly in pediatric cases (NPL 3).
- Hemophilia is a hemorrhagic disease caused by congenital defect or dysfunction of FVIII or FIX among the blood coagulation factors. The disease caused by FVIII abnormality is called hemophilia A and the disease caused by FIX abnormality is called hemophilia B. Severity of the bleeding symptom of hemophilia correlates well with the activity level of the deficient coagulation factor in the blood. Patients with activity of less than 1% are classified as severe, patients with activity of 1% or more and less than 5% are classified as moderate, and patients with activity of 5% or more and less than 40% are classified as mild. Patients with severe symptoms, accounting for approximately half of hemophilia patients, exhibit bleeding symptoms several times a month. This frequency is remarkably high compared to moderate patients and mild patients. Therefore, in patients with severe hemophilia, therapy of replacing the deficient coagulation factor (FVIII or FIX) to maintain the activity of the coagulation factor in the blood at 1% or more is considered to be effective for preventing development of bleeding symptoms (NPL 1).
- For prevention and/or treatment of bleeding in hemophilia patients, coagulation factor formulations (hemophilia A: FVIII; hemophilia B: FIX) purified from plasma or prepared by genetic engineering techniques are mainly used. These formulations are used for on-demand administration to stop bleeding when it occurs, or for preventive administration to prevent development of bleeding events (
NPLs 1 and 4). However, FVIII formulations have a blood half-life of approximately 12 hours, and they therefore need to be administered as frequently as approximately three times a week for the preventive administration (NPLs 5 and 6). The half-life of FIX formulations in blood is 16 hours to 28 hours, and is also reportedly largely different between individuals, ranging from three hours to 38 hours. Thus, for the preventive administration, administering a FIX formulation as frequently as approximately twice a week is a standard protocol (NPLs 5, 6, and 7). In the on-demand administration, formulations must be additionally administered at regular intervals, when necessary, to prevent re-bleeding. In addition, the coagulation factor formulations are administered intravenously. Therefore, there is a strong need for a pharmaceutical agent the administration of which is less burdensome (less frequent administration, and no need for intravenous injection) than the existing coagulation factor formulations. - Moreover, antibodies against the administered coagulation factor formulations (inhibitors) may develop in hemophilia patients (NPL 8). There are reports that for hemophilia A, inhibitors develop in 20% to 30% of severe patients, while for hemophilia B, the development of inhibitors is less frequent than hemophilia A, but occurs in 1% to 6% (NPLs 8 and 9). Such inhibitors cancel the effects of the supplied coagulation factor formulations, making subsequent prevention/treatment with the coagulation factor formulations difficult. For bleeding in patients who have developed inhibitors (inhibitor patients), bypassing agents (activated blood coagulation factor VII (FVII) formulations or APCC formulations) are administered (
NPLs 1 and 8). Their mechanisms of action are less dependent on the function of FVIII formulations or FIX formulations, and may show hemostatic actions even for hemophilia in the presence of inhibitors. However, because of their short half-life of approximately two hours to eight hours in blood, frequent intravenous injections are necessary, and their hemostatic activity is not enough to fully stop bleeding in some cases. Therefore, there is a strong need for a pharmaceutical agent which is not affected by the presence of inhibitors and the administration of which is less burdensome. - Acquired hemophilia, in which blood coagulation factors become impaired due to acquired development of autologous neutralizing antibodies against blood coagulation factors, may be a related bleeding disorder (
NPLs 10 and 11). In most cases, acquired hemophilia is caused by development of anti-FVIII autoantibodies. Bypass formulations and such are administered for bleeding in patients with such acquired bleeding disorders; however, similarly, the problem is that frequent intravenous injections are necessary and there are cases where their hemostatic activity is not enough to fully stop bleeding. - In addition, as bleeding abnormality in which FVIII is involved, von Willebrand disease (von Willebrand's disease) caused by functional abnormality or deficiency of von Willebrand factor (vWF) is known. vWF is not only necessary for platelets to undergo normal adhesion to the subendothelial tissues at lesion sites of vascular walls, but it is also necessary for forming a complex with FVIII and keeping FVIII in the blood at a normal level. In von Willebrand disease patients, these functions are decreased, leading to hemostasis dysfunction (NPL 12). For bleeding in von Willebrand disease patients. FVIII preparations containing desmopressin (DDAVP) or plasma-derived vWF are administered, but similarly, the problem is that frequent intravenous injections are necessary and there are cases where their hemostatic activity is not enough to fully stop bleeding.
- Recently, multispecific antigen-binding molecules which recognize both FIXa and FX, and have a function that substitutes for the cofactor function of FVIII, specifically, the function of promoting the activation of FX by FIXa, have been found (
PTLs 1, 2, and 3). Among the multispecific antigen-binding molecules, bispecific antibodies are being developed as pharmaceutical compositions for prevention and/or treatment of bleeding in hemophilia A (PTLs 1, 2, and 3, and NPLs 13, 14, 15, 16, 17, and 18). Furthermore, application of the bispecific antibodies to prevention and/or treatment of bleeding in acquired hemophilia A and von Willebrand disease, and hemophilia C, which involve dysfunction of FVIII, has also been contemplated (PTLs 1, 2, 3, and 4). In addition, use of the bispecific antibodies in combination with a FIX formulation is also contemplated in the treatment of hemophilia A (PTL 5). - [NPL 1] Guidelines for the management of hemophilia, 2005, World Federation of Hemophilia
- [NPL 2] Alprolix for intravenous administration, package insert, 2017
- [NPL 3] Haemophilia 2011; 17: 2-10
- [NPL 4] Nature 1984; 312: 330-337
- [NPL 5] Nature 1984; 312: 337-342
- [NPL 6] Biochim Biophys Acta 1986; 871: 26
- [NPL 7] Haemophilia 2007; 13: 663-669
- [NPL 8] Blood 2007; 109(2): 546-551
- [NPL 9] Haemophilia 2013; 19: 2-10
- [NPL 10] Semin Thromb Hemost 2012; 38: 433-446
- [NPL 11] Thromb Haemost 2013; 110: 1114-1120
- [NPL 12] Blood 2013; 122: 3735-3740
- [NPL 13] Nature Medicine 2012; 18(10): 1570-1574
- [NPL 14] PLOS ONE 2013; 8(2): e57479
- [NPL 15] J Thromb Haemost 2014; 12(2): 206-213
- [NPL 16] Blood 2014; 124(20): 3165-3171
- [NPL 17] Blood 2016; 127(13): 1633-1641
- [NPL 18] N Engl J Med 2016; 374: 2044-2053
- [PTL 1] WO 2005/035756
- [PTL 2] WO 2006/109592
- [PTL 3] WO 2012/067176
- [PTL 4] WO 2016/171202
- [PTL 5] WO 2016/166014
- An objective of the present invention is to provide pharmaceutical compositions for use in the prevention and/or treatment of FIX disorder, which comprise multispecific antigen-binding molecules that substitute for the function of (functionally substitute for) FVIII.
- In order to solve the above problems, the present inventors examined the blood/plasma coagulation-promoting action (procoagulant activity) of “multispecific antigen-binding molecules substituting for the function of FVIII (FVIII function-substituting molecules)” by coagulation evaluation methods, ROTEM and APTT, using commercially-available FIX-deficient human plasma and blood/plasma derived from patients with FIX disorder.
- As a result, the present inventors discovered that in each of the above-described coagulation evaluation methods, multispecific antigen-binding molecules that functionally substitute for FVIII show procoagul ant activity in blood/plasma derived from FIX disorder patients and in FIX-deficient human plasma. Therefore, multispecific antigen-binding molecules that substitute for the function of FVIII can not only be used as prophylactic (preventive) and/or therapeutic agents against bleeding in hemophilia A, acquired hemophilia A, von Willebrand disease and hemophilia C, which are caused by dysfunction of FVIII, but also as prophylactic and/or therapeutic agents against bleeding in FIX disorder, because of its procoagulant activity.
- Based on these findings, the present invention relates to pharmaceutical compositions for use in the prophylaxis (prevention) and/or treatment of FIX disorder, excluding hemophilia A, acquired hemophilia A, von Willebrand disease and hemophilia C, comprising a multispecific antigen-binding molecule that substitutes for the function of FVIII. More specifically the present invention relates to the following:
- [1] a pharmaceutical composition for use in preventing and/or treating blood coagulation factor
- IX disorder, which comprises a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII;
- [2] the pharmaceutical composition of [1], wherein the multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII is a bispecific antibody which recognizes blood coagulation factor IX and/or activated blood coagulation factor IX, and blood coagulation factor X;
[3] the pharmaceutical composition of [2], wherein the bispecific antibody is: - a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the
H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising theH chain CDR 1, 2, and 3 amino acid sequences of SEQ NOs: 4, 5, and 6 (H chain CDRs of J327), and the third polypeptide and the fourth polypeptide consist of a common L chain comprising theL chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 7, 8, and 9 (L chain CDRs of L404); - [4] the pharmaceutical composition of [2] or [3], wherein the bispecific antibody is:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15;
- [5] the pharmaceutical composition of any one of [2] to [4], wherein the bispecific antibody is:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12.
- [6] The pharmaceutical composition of any one of [1] to [5], wherein the blood coagulation factor IX disorder is a disease that develops and/or progresses due to a decrease, dysfunction, and/or defect in the activity of blood coagulation factor IX and/or activated blood coagulation factor IX:
[7] the pharmaceutical composition of any one of [1] to [6], wherein the blood coagulation factor IX disorder is a congenital or acquired disease;
[8] the pharmaceutical composition of any one of [1] to [7], wherein the blood coagulation factor IX disorder is hemophilia B or blood coagulation factor IX deficiency disease;
[9] the pharmaceutical composition of any one of [1] to [8], which is for combined use with a blood coagulation factor IX formulation;
[10] the pharmaceutical composition of any one of [1] to [8], which is for enhancing the blood coagulation activity of a blood coagulation factor IX formulation;
[11] a combination medicament for use in preventing and/or treating blood coagulation factor IX disorder, which is a combination of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII and a blood coagulation factor IX formulation;
[12] a method of enhancing the blood coagulation activity of a blood coagulation factor IX formulation in a patient with a blood coagulation factor IX disorder, using a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII;
[13] a blood coagulation factor IX formulation for use in combination with the pharmaceutical composition of any one of [1] to [8];
[14] a blood coagulation factor IX formulation for enhancing the FVIII function-substituting activity of the pharmaceutical composition of any one of [1] to [8];
[15] a method for enhancing the FVIII function-substituting activity of a multispecific antigen-binding binding molecule that functionally substitutes for blood coagulation factor VIII in a hemophilia B patient, the method using a blood coagulation factor IX formulation;
[A1] a method for preventing and/or treating a blood coagulation factor IX disorder, which comprises administering to a patient a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII;
[A2] the method of [A1], wherein the multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII is a bispecific antibody which recognizes blood coagulation factor IX and/or activated blood coagulation factor IX, and blood coagulation factor X;
[A3] the method of [A2], wherein the bispecific antibody is the following antibody: - a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, Wherein the first polypeptide consists of an H chain comprising the
H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising theH chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 4, 5, and 6 (H chain CDRs of J327), and the third polypeptide and the fourth polypeptide consist of a common L chain comprising theL chain CDR 1, 2, and 3 amino acid sequences of SEQ NOs: 7, 8, and 9 (L chain CDRs of L404); - [A4] the method of [A2] or [A3], wherein the bispecific antibody is the following antibody:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15;
- [A5] the method of any one of [A2] to [A4], wherein the bispecific antibody is the following antibody:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12; [A6] the method of any one of [A1] to [A5], wherein the blood coagulation factor IX disorder is a disease that develops and/or progresses due to a decrease, dysfunction, and/or defect in the activity of blood coagulation factor IX and/or activated blood coagulation factor IX;
- [A7] the method of any one of [A1] to [A6], wherein the blood coagulation factor IX disorder is a congenital or acquired disease;
[A8] the method of any one of [A1] to [A7], wherein the blood coagulation factor IX disorder is hemophilia B or blood coagulation factor IX deficiency disease;
[A9] the method of any one of [A1] to [A8], which is a combination therapy with a blood coagulation factor IX formulation;
[A10] the method of any one of [A1] to [A8], which is a method for enhancing the blood coagulation activity of a blood coagulation factor IX formulation;
[A11] a method for preventing and/or treating a blood coagulation factor IX disorder, which comprises administering to a patient a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII in combination with a blood coagulation factor IX formulation;
[A12] a method for enhancing the blood coagulation activity of a blood coagulation factor IX formulation, which comprises administering a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII to a patient with a blood coagulation factor IX disorder, wherein the patient is subjected to administration of the blood coagulation factor IX formulation before, simultaneously with, or after administration of the multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII;
[A13] a method for preventing and/or treating blood coagulation factor IX disorder, which comprises administering a blood coagulation factor LX formulation to a patient, wherein the blood coagulation factor IX formulation is administered in combination with a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII;
[A14] a method for enhancing the FVIII function-substituting activity of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII, which comprises administering a blood coagulation factor IX formulation to a hemophilia B patient, wherein the patient is subjected to administration of the multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII before, simultaneously with, or after administration of the blood coagulation factor IX formulation;
[B1] a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII for use in a prevention method and/or a treatment method for a blood coagulation factor IX disorder;
[B2] the antigen-binding molecule of [B1], wherein the multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII is a bispecific antibody which recognizes blood coagulation factor IX and/or activated blood coagulation factor IX, and blood coagulation factor X;
[B3] the antigen-binding molecule of [B2], wherein the bispecific antibody is the following antibody: - a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the
H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising theH chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 4, 5, and 6 (H chain CDRs of J327), and the third polypeptide and the fourth polypeptide consist of a common L chain comprising theL chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 7, 8, and 9 (L chain CDRs of L404); - [B4] the antigen-binding molecule of [B2] or [B3], wherein the bispecific antibody is the following antibody:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15;
- [B5] the antigen-binding molecule of any one of [B2] to [B4], wherein the bispecific antibody is the following antibody:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12;
- [B6] the antigen-binding molecule of any one of [B1] to [B5], wherein the blood coagulation factor IX disorder is a disease that develops and/or progresses due to a decrease, dysfunction, and/or defect in the activity of blood coagulation factor IX and/or activated blood coagulation factor IX;
[B7] the antigen-binding molecule of any one of [B1] to [B6], wherein xe blood coagulation factor IX disorder is a congenital or acquired disease;
[B8] the antigen-binding molecule of any one of [B1] to [B7], wherein the blood coagulation factor IX disorder is hemophilia B or blood coagulation factor IX deficiency disease;
[B9] the antigen-binding molecule of any one of [B1] to [B8], wherein the prevention method and/or the treatment method is a combination therapy with a blood coagulation factor IX formulation;
[B10] the antigen-binding molecule of any one of [B1] to [B8], wherein the prevention method and/or the treatment method is a method for use in enhancing the blood coagulation activity of a blood coagulation factor IX formulation;
[B11] a combination medicament of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII and a blood coagulation factor IX formulation, which is for use in a prevention method and/or treatment method for a blood coagulation factor IX disorder;
[B12] a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII, which is for use in enhancing the blood coagulation activity of a blood coagulation factor IX formulation in a patient with a blood coagulation factor IX disorder;
[B13] a blood coagulation factor IX formulation for use in a prevention method and/or a treatment method for a blood coagulation factor IX disorder, wherein the formulation is administered in combination with the antigen-binding molecule of any one of [B1] to [B8];
[B14] a blood coagulation factor IX formulation for use in enhancing the FVIII function-substituting activity of the antigen-binding molecule of any one of [B1] to [B8];
[B15] a blood coagulation factor IX formulation for use in enhancing the FVIII function-substituting activity of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII in a hemophilia B patient;
[C1] use of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII in the manufacture of a medicament for preventing and/or treating a blood coagulation factor IX disorder;
[C2] the use of [C1], wherein the multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII is a bispecific antibody which recognizes blood coagulation factor IX and/or activated blood coagulation factor IX, and blood coagulation factor X;
[C3] the use of [C2], wherein the bispecific antibody is the following antibody: - a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the
H chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising theH chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 4, 5, and 6 (H chain CDRs of J327), and the third polypeptide and the fourth polypeptide consist of a common L chain comprising theL chain CDR 1, 2, and 3 amino acid sequences of SEQ ID NOs: 7, 8, and 9 (L chain CDRs of L404); - [C4] the use of [C2] or [C3], wherein the bispecific antibody is the following antibody:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of art H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15:
- [C5] the use of any one of [C2] to [C4], wherein the bispecific antibody is the following antibody:
- a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12;
- [C6] the use of any one of [C1] to [C5], wherein the blood coagulation factor IX disorder is a disease that develops and/or progresses due to a decrease, dysfunction, and/or defect in the activity of blood coagulation factor IX and/or activated blood coagulation factor IX;
[C7] the use of any one of [C1] to [C6], wherein the blood coagulation factor IX disorder is a congenital or acquired disease;
[C8] the use of any one of [C1] to [C7], wherein the blood coagulation factor IX disorder is hemophilia B or blood coagulation factor IX deficiency disease;
[C9] the use of any one of [C1] to [C8], wherein the medicament is a combination medicament with a blood coagulation factor IX formulation;
[C10] the use of any one of [C1] to [C8], wherein the medicament is a medicament for enhancing the blood coagulation activity of a blood coagulation factor IX formulation;
[C11] use of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII and a blood coagulation factor IX formulation in the manufacture of a combination medicament for preventing and/or treating a blood coagulation factor IX disorder;
[C12] use of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII in the manufacture of a medicament for enhancing the blood coagulation activity of a blood coagulation factor IX formulation in a patient with a blood coagulation factor IX disorder;
[C13] use of a blood coagulation factor IX formulation in the manufacture of a medicament for preventing and/or treating a blood coagulation factor IX disorder, which is a combination medicament with a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII; and
[C14] use of a blood coagulation factor IX formulation in the manufacture of a medicament for enhancing the FVIII function-substituting activity of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII in a hemophilia B patient. - Pharmaceutical compositions for use in preventing and/or treating FIX disorders other than hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C, the compositions comprising a multispecific antigen-binding molecule that functionally substitutes for FVIII, are provided by the present invention.
-
FIG. 1 shows the shortening ratios of blood coagulation (initiation) time according to Ca-triggered Whole blood coagulability test (ROTEM) using blood samples from FIX disorder patients under regular administration therapy. -
FIG. 2 shows the ratio of APTT shortening when ACE910 (100 μg/mL) was added ex vivo to plasma from FIX disorder patients. The abbreviations in the figure are explained below. - ACE: ACE910
- sFIXd: commercially available FIX-deficient human plasma (Sysmex)
- CogtrN: commercially available standard human plasma (Coagtrol N, Sysmex)
- FIX:C: FIX activity level
- FIX:Ag: FIX antigen level
-
FIG. 3-1 shows evaluation of the ratio of APTT shortening determined from values before and after addition of 100 μg/mL ACE910, when a FIX formulation (rFIX, BeneFix, Pfizer) at a concentration of 0, 0.01, 0.1, 1, 10, or 100 IU/dL, or an anti-FIX-Gla antibody (anti-FIX Ab) was added to a commercially available FIX-deficient human plasma (FIXd-plasma or sFIXd) and this was subjected to further ex vivo addition of ACE910. -
FIG. 3-2 shows the result obtained by further adding an anti-FIX-Gla antibody (aFIXAb) to the FIX-deficient human plasma ex vivo. - The multispecific antigen-binding molecule that substitutes for the function of FVIII of the present invention can also be referred to as a multispecific antigen-binding molecule having FVIII-like activity. In the present invention, the phrase “functionally substitute/substituting for FVIII (substitute/substituting for the function of FVIII)” means that FX activation by FIXa is promoted (FXa generation by FIXa is promoted). More specifically, in the present invention, the phrase “functionally substitute/substituting for FVIII (substitute/substituting for the function of FVIII)” means recognizing FIX and/or FIXa, and FX, and promoting activation of FX by FIXa (promoting FXa generation by FIXa). The activity of promoting FXa generation can be evaluated by methods well known in the art, for example using a measurement system comprising FIXa, FX, synthetic substrate S-2222 (synthetic substrate of FXa), and phospholipids. In more detail, evaluations can be carried out according to the methods described in WO 2005/035756, WO 2006/109592, WO 2012/067176, or such.
- Multispecific antigen-binding molecules of the present invention comprise a first antigen-binding site and a second antigen-binding site that can specifically bind to at least two different types of antigens or epitopes. While the first antigen-binding site and the second antigen-binding site are not particularly limited as long as they have an activity to bind to FIX and/or FIXa, and FX, respectively, examples include sites necessary for binding with antigens, such as antibodies, scaffold molecules (antibody-like molecules) or peptides, or fragments containing such sites. Scaffold molecules are molecules that exhibit function by binding to target molecules, and any polypeptide may be used as long as they are conformationally stable polypeptides that can bind to at least one target antigen. Examples of such polypeptides include antibody variable regions, fibronectin (WO 2002/032925) protein A domain (WO 1995/001937), LDL receptor A domain (WO 2004/044011, WO 2005/040229), ankyrin (WO 2002/020565), and such, and also molecules described in documents by Nygren et al. (Current Opinion in Structural Biology 1997; 7: 463-469; and Journal of Immunol Methods 2004; 290: 3-28), Binz et al. (Nature Biotech 2005; 23: 1257-1266), and Hosse et al. (Protein Science 2006; 15: 14-27). Furthermore, as mentioned in Curr Opin Mol Ther 2010; 12(4): 487-95 and Drugs 2008; 68(7). 901-12, peptide molecules that can bind to target antigens may be used.
- In the present invention, multispecific antigen-binding molecules are not particularly limited as long as they are molecules that can bind to at least two different types of antigens or epitopes, but examples include polypeptides containing the above-mentioned antigen-binding sites, such as antibodies and scaffold molecules as well as their fragments, and aptamers comprising nucleic acid molecules and peptides, and they may be single molecules or multimers thereof. Preferred multispecific antigen-binding molecules include multispecific antibodies that can bind specifically to at least two different antigens. Particularly preferred examples of multispecific antibodies of the present invention include bispecific antibodies (BsAb) that can bind specifically to two different antigens (they may also be called dual specific antibodies).
- In the present invention, the term “common L chain (commonly shared L chain)” refers to an L chain that respectively forms a pair with two or more different H chains, and can show binding ability to each antigen. Herein, the term “different H chain(s)” preferably refers to H chains of antibodies against different antigens, but is not limited thereto, and also refers to H chains whose amino acid sequences are different from each other. Commonly shared L chain can be obtained, for example, according to the method described in WO 2006/109592.
- In an embodiment of the present invention, when multispecific antigen-binding molecules, multispecific antibodies, or bispecific antibodies of the present invention respectively have a plurality of antibody L chains, those antibody L chains may be different from one another or they may be a common L chain.
- In an embodiment of the present invention, a multispecific antigen-binding molecule is a multispecific antigen-binding molecule that recognizes FIX and/or FIXa, and FX, and functionally substitutes for FVIII; preferably a multispecific antibody that recognizes FIX and/or FIXa, and FX, and functionally substitutes for FVIII; and more preferably a bispecific antibody that recognizes FIX and/or FIXa, and FX, and functionally substitutes for FVIII. The antigen-binding molecule or the antibody of the present invention preferably comprises variable regions in an anti-FIXa antibody and variable regions in an anti-FX antibody.
- In one embodiment of the present invention, the multispecific antigen-binding molecule, multispecific antibody, or bispecific antibody comprises a first polypeptide and a third polypeptide comprising an antigen-binding site that recognizes FIX and/or FIXa, and a second polypeptide and a fourth polypeptide comprising an antigen-binding site that recognizes FX. The first polypeptide and the third polypeptide, and the second polypeptide and the fourth polypeptide, include the antigen-binding site of an antibody H chain and the antigen-binding site of an antibody L chain.
- For example, in the multispecific antigen-binding molecule, multispecific antibody, or bispecific antibody in the present invention, the first polypeptide and the third polypeptide contain the antigen-binding site of an H chain and an L chain, respectively, of an antibody against FIX or FIXa, and the second polypeptide and the fourth polypeptide contain the antigen-binding site of an H chain and an L chain, respectively, of an antibody against FX. In this case, the antibody L chain antigen-binding sites contained in the first polypeptide and the third polypeptide, and in the second polypeptide and the fourth polypeptide, may be the antigen-binding site of a common L chain.
- In the present invention, the polypeptides comprising an antibody L chain antigen-binding site preferably contain the sequence of the whole or a part of the L chain of an antibody binding to FIX, FIXa and/or FX.
- A preferred embodiment of multispecific antigen-binding molecule that functionally substitutes for FVIII in the present invention includes, for example, a bispecific antibody that recognizes FIX and/or FIXa, and FX. Such an antibody can be obtained according to methods described, for example, in WO 2005/035756, WO 2006/109592, and WO 2012/067176. The bispecific antibody of the present invention includes antibodies described in these documents.
- A preferred bispecific antibody includes the antibody (ACE910: Emicizumab) below, which is a bispecific antibody described in a patent document (WO 2012/067176):
- a bispecific antibody in which a first polypeptide forms a pair with a third polypeptide and a second polypeptide forms a pair with a fourth polypeptide, wherein the first polypeptide consists of an H chain comprising the amino acid sequences of
H chain CDR 1, 2, and 3 of SEQ ID NOs: 1, 2, and 3 (H chain CDRs of Q499), the second polypeptide consists of an H chain comprising the amino acid sequences ofH chain CDR 1, 2, and 3 of SEQ ID NOs: 4, 5, and 6 (H chain CDRs of J327), and the third and fourth polypeptides consist of a common L chain comprising the amino acid sequences ofL chain CDR 1, 2, and 3 of SEQ ID NOs: 7, 8, and 9. - More specifically, the antibody is a bispecific antibody in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 13, the second polypeptide consists of an H chain comprising the H chain variable region amino acid sequence of SEQ ID NO: 14, and the third polypeptide and the fourth polypeptide consist of a common L chain comprising the L chain variable region amino acid sequence of SEQ ID NO: 15.
- More specifically, the antibody is a bispecific antibody (Q499-z121/J327-z119/L404-k) in which a first polypeptide and a third polypeptide form a pair and a second polypeptide and a fourth polypeptide form a pair, wherein the first polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 10, the second polypeptide consists of an H chain consisting of the amino acid sequence of SEQ ID NO: 11, and the third polypeptide and the fourth polypeptide consist of a common L chain of SEQ ID NO: 12.
- Amino acids contained in the amino acid sequences described in the present invention may be post-translationally modified (for example, the modification of an N-terminal glutamine into a pyroglutamic acid by pyroglutamylation is well-known to those skilled in the art). Naturally, antibodies with such post-translationally modified amino acids are included in the antibodies used in the present invention.
- Herein, the term “recognize(s)” in the phrase “an antibody which recognizes antigen A”, the term “bind(s)” in the phrase “an antibody which binds to antigen A”, and the term “specifically bind(s)” in the phrase “an antibody which specifically binds to antigen A” may be used interchangeably in a broad sense.
- Polypeptides in the present invention normally refer to proteins and peptides having a length of approximately ten amino acids or longer. Generally, they are biologically derived polypeptides, but are not particularly limited to such polypeptides, and may be, for example, polypeptides comprising an artificially designed sequence. Furthermore, they may be any native polypeptides, or synthetic polypeptides, recombinant polypeptides, or such. Additionally, the fragments of the above-mentioned polypeptides are also included in the polypeptides of the present invention.
- The term “antibody” is used in the broadest sense, and may be monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (for example, bispecific antibodies), antibody derivatives, and modified antibody products (Miller K et al J Immunol. 2003, 170(9), 4854-61) as long as they display a desired biological activity. The antibodies may be mouse antibodies, human antibodies, humanized antibodies, chimeric antibodies, or those derived from another species, or they may be artificially synthesized antibodies. The antibodies disclosed herein can be of any type (for example, IgG, IgE, IgM, IgD, and IgA), class (for example, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecules. The immunoglobulins can be derived from any species (for example, human, mouse, or rabbit). The terms “antibody”, “immune globulin” and “immunoglobulin” are used interchangeably in a broad sense.
- The term “antibody derivative” includes a portion of an antibody, preferably an antibody variable domain, or at least an antigen-binding region of an antibody. Antibody derivatives include, for example, Fab, Fab′, F(ab′)2, Fv fragments, linear antibodies, and single-chain antibodies (scFv), sc(Fv)2, Fab3, domain antibodies (dAb) (WO 2004/058821, WO 2003/002609), diabodies, triabodies, tetrabodies, minibodies, and multispecific antibodies formed from antibody derivatives, but are not limited thereto. Here, “Fab” is constructed from a single light chain and the CH1 domain and variable region of a single heavy chain. Furthermore, “Fv” is the smallest antibody derivative, and includes a complete antigen-recognizing region and an antigen-binding region. The antibody derivative may be, for example, a fusion between an IgG antibody and Fc. For example, one can refer to Example 2 in U.S. Pat. No. 5,641,870 specification; Zapata Get at. Protein Eng. 1995, 8(10), 1057-1062; Olafsen T et al. Protein Eng. Design & Sel. 2004, 17(4): 315-323; Holliger P et al. Nat. Biotechnol. 2005, 23(9): 1126-36; Fischer N et al. Pathobiology. 2007, 74(1): 3-14; Shen J et al, J Immunol Methods. 2007, 318, 65-74; and Wu et al. Nat Biotechnol. 2007, 25(11), 1290-7.
- Diabodies are bivalent low-molecular weight antibodies (minibodies) constructed by gene fusion (Holliger, P. et al., Proc. Natl. Acad. Sci. USA 1993; 90: 6444-6448; EP 404,097; WO 93/11161), Diabodies are dimers consisting of two polypeptide chains, in which each polypeptide chain comprises an L chain variable region (VL) and an H chain variable region (VH) linked with a linker short enough to prevent association of these two domains within the same chain, for example, a linker of preferably 2 to 12 amino acids, more preferably 3 to 10 amino acids, particularly about 5 amino acids. The polypeptide chain form a dimer since the linker between the VL and VH encoded on the same polypeptide is too short to form a single chain variable region fragment. Therefore, diabodies comprise two antigen-binding sites.
- A single-chain antibody or an scFv antibody fragment comprises the VH and VL regions of an antibody, and these regions exist in a single polypeptide chain. In general, an Fv polypeptide further comprises a polypeptide linker between the VH and VL regions, and this enables an scFv to form a structure necessary for antigen binding (for a review on scFvs, see Pluckthun “The Pharmacology of Monoclonal Antibodies” Vol. 113 (Rosenburg and Moore ed. (Springer Verlag, New York) pp. 269-315, 1994). In the context of the present invention, linkers are not particularly limited so long as they do not inhibit the expression of the antibody variable regions linked at their ends.
- Bispecific antibodies may be produced by chemically crosslinking Fab′s. Bispecific F(ab′)2 can be produced, for example, by preparing Fab′ from an antibody, using it to produce a maleimidized Fab′ with ortho-phenylenedi-maleimide (o-PDM), and then reacting this with Fab′ prepared from another antibody to crosslink Fab′s derived from different antibodies (Keler T et al. Cancer Research 1997, 57: 4008-4014). The method of chemically linking an Fab′-thionitrobenzoic acid (TNB) derivative and an antibody fragment such as Fab′-thiol (SH) is also known (Brennan M et al. Science 1985; 229: 81-83),
- Instead of a chemical crosslink, a leucine zipper derived from Fos and Jun may also be used. Preferential formation of heterodimers by Fos and Jun is utilized, even though they also form homodimers. Fab′ to which Fos leucine zipper is added, and another Fab′ to which Jun leucine zipper is added are expressed and prepared. Monomeric Fab′-Fos and Fab′-Jun reduced under mild conditions are mixed and reacted to form bispecific F(ab′)2 (Kostelny S A et at. J. of Immunology, 1992, 148: 1547-53). This method can be applied not only to Fab′s but also to scFvs, Fvs, and such.
- Furthermore, bispecific antibodies including sc(Fv)2 such as IgG-scFv (Protein Eng Des Sel. 2010; 23(4): 221-8) and BiTE (Drug Discov Today 2005; 15; 10(18): 1237-44), DVD-Ig (Nat Biotechnol. 2007; 25(11): 1290-7. Epub 2007 Oct 14; and MAbs 2009; 1(4): 339-47. Epub 2009 Jul. 10), and also others (IDrugs 2010; 13: 698-700) including two-in-one antibodies (Science 2009; 20; 323(5921): 1610-4; and Immunotherapy 2009; 1(5): 749-51), Tri-Fab, tandem scFv, and diabodies are known (MAbs 2009; 1(6): 539-547). In addition, even when using molecular forms such as scFv-Fc and scaffold-Fc, bispecific antibodies can be produced efficiently by preferentially secreting a heterologous combination of Fcs (Ridgway J B et al., Protein Engineering 1996; 9: 617-621; Merchant AM et al. Nature Biotechnology 1998; 16: 677-681; WO 2006/106905; and Davis J H et al., Protein Eng Des Sel 2010; 4: 195-202).
- A bispecific antibody may also be produced using a diabody. A bispecific diabody is a heterodimer of two cross-over scFv fragments. More specifically, it is produced by forming a heterodimer using VH(A)-VL(B) and VH(B)-VL(A) prepared by linking VHs and VLs derived front two kinds of antibodies, A and B, using a relatively short linker of about 5 residues (Holliger P et al. Proc Natl. Acad. Sci. USA 1993; 90: 6444-6448).
- The desired structure can be achieved by linking the two scFvs with a flexible and relatively long linker comprising about 15 residues (single chain diabody: Kipriyanov S M et at. J. of Molecular Biology 1999; 293: 41-56), and conducting appropriate amino acid substitutions (knobs-into-holes: Zhu Z et al. Protein Science 1997; 6: 781-788; VH/VL interface engineering: Igawa T et al. Protein Eng Des Sel 2010; 8: 667-77).
- An sc(Fv)2 that can be produced by linking two types of scFvs with a flexible and relatively long linker, comprising about 15 residues, may also be a bispecific antibody (Mallender W D et al. J. of Biological Chemistry 1994; 269: 199-206).
- Examples of modified antibody products may include antibodies linked to various molecules such as polyethylene glycol (PEG). Antibodies of the present invention include such modified antibody products. The substance to be linked is not limited in the modified antibody products of the present invention. To yield such modified antibody products, chemical modifications can be made to the obtained antibodies. Such methods are already established in this field.
- “Bispecific” antibodies refer to antibodies having variable regions that recognize different epitopes, where the regions are within the same antibody molecule. Bispecific antibodies may be antibodies that recognize two or more different antigens or antibodies that recognize two or more different epitopes on the same antigen. Bispecific antibodies may include not only whole antibodies but antibody derivatives. Antibodies of the present invention also include bispecific antibodies. Herein, anti-FIXa/FX bispecific antibody and bispecific antibody that recognizes FIXa and FX are used synonymously.
- Recombinant antibodies produced by using genetic engineering techniques can be used as the antibodies. Recombinant antibodies can be obtained by cloning DNAs encoding the antibodies from hybridomas or antibody-producing cells such as sensitized lymphocytes that produce antibodies, inserting them into vectors, and then introducing them into hosts (host cells) to produce the antibodies.
- The antibodies include human antibodies, mouse antibodies, and rat antibodies, and their origin is not limited. They may also be genetically modified antibodies such as chimeric antibodies and humanized antibodies.
- Methods for obtaining human antibodies are known. For example, transgenic animals carrying the entire repertoire of human antibody genes can be immunized with antigens of interest to obtain human antibodies of interest (see International Publication WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).
- Genetically modified antibodies can be produced using known methods. Specifically, for example, chimeric antibodies comprise H chain and L chain variable regions of an immunized animal antibody, and H chain and L chain constant regions of a human antibody. Chimeric antibodies can be obtained by linking DNAs encoding the variable regions of the antibody derived from the immunized animal, with DNAs encoding the constant regions of a human antibody, inserting this into an expression vector, and then introducing it into host to produce the antibodies.
- Humanized antibodies are modified antibodies that are also referred to as reshaped human antibodies. A humanized antibody is constructed by transferring the complementarity determining regions (CDRs) of an antibody derived from an immunized animal to the CDRs of a human antibody. Conventional genetic recombination techniques for such purposes are known (see European Patent Application Publication No. EP 239400; international Publication No. WO 96/02576; Sato K et al., Cancer Research 1993, 53: 851-856; international Publication No. WO 99/51743).
- While bispecific antibodies are not limited to those of the IgG type, for example, IgG-type bispecific antibodies can be secreted from a hybrid hybridoma (quadroma) produced by fusing two types of hybridomas that produce IgG antibodies (Milstein C. et al, Nature 1983, 305: 537-540). They can also be secreted by introducing the L chain and H chain genes constituting the two types of IgGs of interest, a total of four types of genes, into cells to co-express the genes.
- In this case, by introducing suitable amino acid substitutions to the CH3 regions of the H chains, IgGs having a heterogeneous combination of H chains can be preferentially secreted (Ridgway J B et al. Protein Engineering 1996, 9: 617-621; Merchant A M et al. Nature Biotechnology 1998, 16: 677-681; WO 2006/106905; Davis J H et al. Protein Eng Des Sel. 2010, 4: 195-202).
- Regarding the L chains, since the diversity of L chain variable regions is lower than that of H chain variable regions, one can expect to obtain common L chain that can confer binding ability to both H chains. The antibodies of the present invention may be antibodies comprising common L chains. Bispecific IgGs can be efficiently expressed by introducing the gene of the common L chain and both H chains into cells.
- Antibodies of the present invention can be produced by methods known to those skilled in the art. Specifically, DNA encoding the antibody of interest is inserted into an expression vector. Insertion into an expression vector is carried out such that the expression will take place under the control of expression regulatory regions such as enhancers and promoters. Next, host cells are transformed using this expression vector to express the antibodies. Appropriate combinations of the host and expression vector can be used in this step.
- Examples of the vectors include M13 series vectors, pUC series vectors, pBR322, pBluescript, and pCR-Script. In addition to these vectors, for example, pGEM-T, pDIRECT, or pT7 can also be used for the purpose of cDNA subcloning and excision.
- Particularly, expression vectors are useful for using the vectors for the purpose of producing the antibody. For example, when the host is E. coli such as JM109, DH5α, HB101, or XL1-Blue, the expression vectors indispensably have a promoter that permits efficient expression in E. coli, for example, lacZ promoter (Ward et al., Nature (1989) 341, 544-546; and FASEB J (1992) 6, 2422-2427), araB promoter (Better et al., Science (1988) 240, 1041-1043), or T7 promoter. Examples of such vectors include the vectors mentioned above as well as pGEX-5X-1 (manufactured by Pharmacia). “QIAexpress system” (manufactured by QIAGEN), pEGFP, and pET (in this case, the host is preferably BL21 expressing T7 RNA polymerase).
- The vectors may contain a signal sequence for polypeptide secretion. In the case of production in the periplasm of E coli, pelB signal sequence (Lei, S. P. et al., J. Bacteriol. (1987) 169, 4397) can be used as the signal sequence for polypeptide secretion. The vectors can be transferred to the host cells using, for example, calcium chloride methods or electroporation methods.
- In addition to the E. coli expression vectors, examples of the vectors for producing the antibody of the present invention include mammal-derived expression vectors (e.g., pcDNA3 (manufactured by Invitrogen Corp.), pEGF-BOS (Nucleic Acids. Res. 1990, 18(17), p5322), pEF, and pCDM8), insect cell-derived expression vectors (e.g., “Bac-to-BAC baculovairus expression system” (manufactured by GIBCO BRL), and pBacPAK8), plant-derived expression vectors (e.g., pMH1 and PMH2), animal virus-derived expression vectors (e.g., pHSV, pMV, and pAdexLcw), retrovirus-derived expression vectors (e.g., pZIPneo), yeast-derived expression vectors (e.g., “Pichia Expression Kit” (manufactured by Invitrogen Corp.), pNV11, and SP-Q01), and Bacillus subtilis-derived expression vectors (e.g., pPL608 and pKTH50).
- For the purpose of expression in animal cells such as CHO cells, COS cells, or NIH3T3 cells, the vectors indispensably have a promoter necessary for intracellular expression, for example, SV40 promoter (Mulligan et al., Nature (1979) 277, 108), MMTV-LTR promoter, EF1α promoter (Mizushima et al., Nucleic Acids Res (1990) 18, 5322), CAG promoter (Gene (1991) 108, 193), or CMV promoter and, more preferably, have a gene for screening for transformed cells (e.g., a drug resistance gene that can work as a marker by a drug (neomycin, G418, etc.)). Examples of the vectors having such properties include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.
- An exemplary method intended to stably express the gene and increase the number of intracellular gene copies involves transfecting CHO cells deficient in nucleic acid synthesis pathway with vectors having a DHFR gene serving as a complement thereto (e.g., pCHOI) and using methotrexate (MTX) in the gene amplification. An exemplary method intended to transiently express the gene involves using COS cells having a gene which expresses an SV40 T antigen on their chromosomes to transform the cells with vectors having a replication origin of SV40 (pcD, etc). A replication origin derived from polyomavirus, adenovirus, bovine papillomavirus (BPV), or the like may be used. The expression vectors for increasing the number of gene copies in a host cell system can additionally contain a selection marker such as an aminoglycoside transferase (APH) gene, a thymidine kinase (TK) gene, an E. coli xanthine guanine phosphoribosyltransferase (Ecogpt) gene, or a dihydrofolate reductase (dhfr) gene.
- The antibodies of the present invention obtained by the methods described above can be isolated from inside host cells or from outside of the cells (the medium, or such), and purified to practically pure and homogeneous antibodies. The antibodies can be separated and purified by methods routinely used for separating and purifying antibodies, and the type of method is not limited. For example, the antibodies can be separated and purified by appropriately selecting and combining column chromatography, filtration, ultrafiltration, salting-out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectrofocusing, dialysis, recrystallization, and such.
- The chromatographies include, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et ai., Cold Spring Harbor Laboratory Press, 1996). The chromatographic methods described above can be conducted using liquid-chromatography, for example, HPLC and FPLC. Columns used for affinity chromatography include protein A columns and protein G columns. Columns using protein A include, for example, Hyper D, POROS, and Sepharose FF (GE Amersham Biosciences). The present invention includes antibodies that are highly purified using these purification methods.
- Pharmaceutical compositions used for therapeutic or preventive purposes of the present invention can be prepared by mixing, if necessary, with suitable pharmaceutically acceptable carriers, vehicles, and such, and then made into lyophilized formulations or solution formulations. Examples of suitable pharmaceutically acceptable carries and vehicles include sterilized water, physiological saline, stabilizers, excipients, antioxidants (such as ascorbic acid), buffers (such as phosphate, citrate, histidine, and other organic acids), antiseptics, surfactants (such as PEG and Tween), chelating agents (such as EDTA), and binders. They may also comprise other low-molecular-weight polypeptides, proteins such as serum albumin, gelatin, and immunoglobulins, amino acids such as glycine, glutamine, asparagine, glutamic acid, asparagic acid, methionine, arginine, and lysine, sugars and carbohydrates such as polysaccharides and monosaccharides, and sugar alcohols such as mannitol and sorbitol. When preparing an aqueous solution for injection, physiological saline and isotonic solutions comprising glucose and other adjuvants such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride may be used, and if necessary, in combination with appropriate solubilizers such as alcohol (for example, ethanol), polyalcohols (such as propylene glycol and PEG), and nonionic surfactants (such as polysorbate 80,
polysorbate 20, poloxamer 188, and HCO-50). By mixing hyaluronidase into the formulation, a larger fluid volume can be administered subcutaneously (Expert Opin Drug Deliv. 2007 July; 4(4): 427-40). Alternatively, the pharmaceutical compositions of the present invention may be filled into syringes in advance. Solution formulations can be prepared according to methods described in WO 2011/090088. - The pharmaceutical compositions of the present invention can be administered to patients via any suitable route. For example, patients can be treated with bolus or continuous infusion over a period of time via an intravenous, intramuscular, intraperitoneal, intracerebral, transdermal, subcutaneous, intraarticular, sublingual, intrasynovial, oral, inhalation, topical or external route. Intravenous administration or subcutaneous administration is preferred. Patients in the present application include human patients and non-human animal patients. In the present application, the term “patient” is used interchangeably with “subject” and “individual”.
- The dosage is, for example, 0.001 mg/kg to 1000 mg/kg in the case of the above-mentioned bispecific antibody. The administration interval is at least one day or longer in the case of the above-mentioned bispecific antibody.
- Rotation thromboelastometry (ROTEM), activated partial thromboplastin time (APTT), clot waveform analysis (CWA), thrombin generation assay (TGA), and such are widely known as methods for monitoring the drug efficacy of blood coagulation factors such as FVIII, and those skilled in the art can use them by appropriately changing/modifying these methods. These methods may be used alone or in combination, and the drug efficacy may be determined from the results of at least one method.
- ROTEM is an examination method that can comprehensively evaluate the coagulability and coagulation process of blood by monitoring a thrombelastograph (change in elasticity of clotted blood). It is generally used for analyzing causes of bleeding and for determining effects of therapeutic agents. A reaction-initiating reagent such as a Ca trigger is added to a test blood, and clotting time (CT), clot formation time (CFT), and such are measured as evaluation parameters.
- APTT has long been widely used as a method for monitoring the drug efficacy of FVIII formulations. APTT is a method in which an APTT reagent is added to test plasma, after which CaCl2 is added, and the time for fibrinogen to be converted into insoluble fibrin, that is, the time until coagulation starts, is measured.
- CWA is a test in which the amount of fibrin generated as the coagulation reaction progresses is measured as optical (e.g., absorbance) changes over time. In CWA, a series of coagulation reactions from the initiation stage of fibrin formation to the amplification stage of the coagulation reaction can be evaluated over time. Furthermore, as for the coagulation-initiating reagent for CWA, the APTT reagent (Thromb Haemost 2002; 87 (3): 436-41, J Thromb Haemost 2006; 4 (2): 377-84)), a reagent with a mixed solution of a low concentration of tissue factor (TF) and a blood coagulation factor XII (FXII) activator (ellagic acid) (J Thromb Haemost 2014; 12 (3): 355-62), and such reagents have been reported. The clot waveform is a waveform representing a temporal change in optical information (absorbance) related to the amount of light. The clot waveform is differentiated (first differentiation) to calculate the coagulation velocity, and the maximum coagulation velocity is used as a parameter. The coagulation velocity is differentiated (secondary differentiation) to calculate coagulation acceleration, and the maximum coagulation acceleration is used as a parameter (Haemophilia 2008; 14: 83-92, J Thromb Haemost 2014; 12 (3): 355-62).
- TGA is an assay in which the amount of thrombin generated as the coagulation reaction progresses is measured as enzymatic activity over time using a fluorescent substrate for thrombin (Haemophilia 2008; 14 (suppl. 3): 83-92).
- In one embodiment of the present invention, pharmaceutical compositions used for the prevention and/or treatment of an FIX disorder, which comprise a multispecific antigen-binding molecule that substitutes for the function of FVIII, are provided. FIX disorders are rare hemorrhagic diseases caused by a congenital defect or dysfunction of FIX, and include, for example, hemophilia B and FIX deficiency disease. In addition, the decreased activity or defect of FIX includes, for example, those from congenital and/or acquired causes, but is not limited thereto. The degree of decrease in FIX activity in patients compared to normal subjects is preferably less than 40% (for example, less than 40%, less than 30%, less than 20%, less than 10%), more preferably less than 10% (for example, less than 10%, less than 9%, or less than 8%, less than 7%, or less than 6%), even more preferably less than 5% (e.g., less than 5%, less than 4%, less than 3%, or less than 2%), particularly preferably less than 1%, but is not limited thereto. Methods for measuring the activity of FIX are well known to those skilled in the art (for example, “Minna ni yakudatsu ketsuyuubyou no kiso to rinsho” (Basics and clinical practice of hemophilia useful for all), Satoshi Shirahata, Iyaku Journal, 2009, etc.).
- In an embodiment of the present invention, hemophilia B patients or patients with FIX deficiency disease include patients with or without inhibitors (autoantibodies against FIX), patients with a decrease or a complete lack of FIX level, and patients with a decrease or a complete lack of FIX activity, but are not particularly limited thereto.
- In one aspect, hemophilia B patients or FIX deficiency disease patients are severe hemophilia B patients or severe FIX deficiency disease patients with a trace FIX activity of less than 1.0 IU/dL. In one aspect, hemophilia B patients or FIX deficiency disease patients are hemophilia B patients or FIX deficiency disease patients who do not carry inhibitors.
- The terms “hemophilia B” and “FIX deficiency disease” are used interchangeably in a broad sense.
- In an embodiment, the present invention provides pharmaceutical compositions for use in preventing and/or treating blood coagulation factor IX disorder, which comprise a multispecific antigen-binding molecule that functionally substitutes for FVIII, wherein the compositions are for combined use with blood coagulation factor IX formulations (FIX formulations). In the combined use, these pharmaceutical agents may be administered simultaneously or consecutively, or one may be administered first and then the other may be administered after a period of time.
- In another aspect, the present invention provides pharmaceutical compositions for use in preventing and/or treating blood coagulation factor IX disorder, which comprise a multispecific antigen-binding molecule that functionally substitutes for FVIII, wherein the composition is for enhancing the blood coagulation activity of FIX formulations.
- Furthermore, in another aspect, the present invention provides combination medicaments for use in preventing and/or treating blood coagulation factor IX disorder, which are a combination of a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII and a FIX formulation.
- In addition, in another aspect, the present invention provides methods for enhancing the blood coagulation activity of FIX formulations in patients with a blood coagulation factor IX disorder, using a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII.
- The phrase “enhancing blood coagulation activity” refers to, for example, shortening of APTT by administering the multispecific antigen-binding molecule by at least one second, preferably by at least three seconds or five seconds, and more preferably by at least ten seconds, compared to that before administering the multispecific antigen-binding molecule.
- Furthermore, in another aspect, the present invention provides blood coagulation factor IX formulations for combined use with the pharmaceutical composition for use in preventing and/or treating blood coagulation factor IX disorder, which comprises a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII.
- Furthermore, the present invention provides blood coagulation factor IX formulations for enhancing the FVIII function-substituting activity of the pharmaceutical compositions for use in preventing and/or treating blood coagulation factor IX disorder, which comprise a multispecific antigen-binding molecule that functionally substitutes for blood coagulation factor VIII.
- Furthermore, the present invention provides methods for enhancing the FVIII function-substituting activity of multispecific antigen-binding molecules that functionally substitute for blood coagulation factor VIII in patients with blood coagulation factor IX disorder, using a blood coagulation factor IX formulation.
- The FIX formulation may be any pharmaceutical composition comprising FIX regardless of the origin and molecular form of FIX, and includes Christmassin M, Novact M, PPSB-HT, BeneFIX (nonacog alfa), Rixubis (nonacog gamma), Alprolix (eftrenonacog alfa), and Idelvion (albutrepenonacog alfa), but is not particularly limited thereto.
- In one embodiment of the present invention, FIX is not limited to human-derived FIX, and may be FIX derived from humans, bovines, pigs, dogs, cats, or mice/rats. In one aspect, FIX is a human FIX, which refers to a human FIX consisting of 415 amino acid residues, which is formed by removing the N-terminal signal sequence and the pro-peptide region consisting of 46 amino acids from the immature human FIX consisting of 461 amino acid residues (SEQ ID NO: 16) (see for example, UniProtKB/Swiss-Prot Accession P00740-1). Human FIX is shown by positions 47 to 461 of SEQ ID NO: 16. FIX includes any form of FIX which has the typical features of FIX. Generally, FIX contains a GLA domain (a domain containing γ-carboxyglutamate residues), two EGF domains (human EGF homology domains), an activation peptide domain, and a C-terminal protease domain. However, FIX is not necessarily limited to FIX containing the above, and it may contain domains known in this technical field that are synonymous to these domains, or partially-deleted fragments thereof. FIX or sequence variants thereof are not limited to the following, but they have been cloned as described in U.S. Pat. Nos. 4,770,999 and 7,700,734, and cDNAs encoding human FIX have been isolated (see for example, Choo et al., Nature 299: 178-180 (1982); Fair et al., Blood 64: 194-204 (1984); and Kurachi et al., Proc. Natl. Acad. Sci., U.S.A. 79: 6461-6464 (1982)). These known sequence variants include those carrying amino acid substitutions that enhance the functions of FIX and amino acid substitutions that prolong the half-life of FIX. Furthermore, as long as the objective of the present invention can be accomplished, various FIX variants (for example, FIX into which amino acid sequence mutations are artificially introduced) and various modified forms of FIX (for example, PEGylated FIX) may be used. Herein below, the term “FIX” is simply mentioned in the present application it includes its sequence variants, FIX variants, and modified forms FIX, unless specifically noted otherwise.
- As used herein, embodiments represented by the expression “comprising . . . ” may include embodiments represented by the expression “essentially consisting of . . . ” and embodiments represented by the expression “consisting of . . . ”.
- All patents and reference documents explicitly cited herein are incorporated by reference into this description in their entirety.
- The present invention will be further illustrated by the Examples, but it is not to be construed as being limited thereto.
- Herein below, the present invention will be specifically described by the Examples, but it is not to be construed as being limited thereto.
- In the present invention, the blood/plasma procoagulant activity of a multispecific antigen-binding molecule that functionally substitutes for FVIII was examined using blood or plasma from FIX disorders other than hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C. More specifically, the blood/plasma procoagulant activity of ACE910 (Emicizumab), which is the bispecific antibody described in a patent document (WO 2012/067176) and is one of the aforementioned multispecific antigen-binding molecules, was examined by each of the coagulation evaluation methods, ROTEM and APTT, using blood/plasma derived from hemophilia B patients and a commercially-available FIX-deficient human plasma (George King Bio-Medical).
- ACE910 was obtained by the methods described in WO 2005/035756, WO 2006/109592, and WO 2012/067176. The bispecific antibody was expressed by incorporating the antibody genes into animal cell expression vectors and transfecting them into CHO cells, The bispecific antibody contained in the cell culture supernatant was then purified.
- The FVIII function-substituting activity of the thus purified hispecific antibody was measured by the enzyme assay shown below. At room temperature, 1 nM human FIXa (Enzyme Research Laboratories), 140 nM human FX (Enzyme Research Laboratories), 20 μM phospholipids (10% phosphatidylserine, 60% phosphatidylcholine, 30% phosphatidylethanolamine), and the hispecific antibody were mixed with Tris-buffered saline solution containing 5 mM CaCl2 and 0.1% bovine serum albumin, and incubated for 2 minutes to cause the FX activation reaction by FIXa to proceed. This reaction was terminated by adding EDTA. Subsequently, FXa-specific chromogenic substrate solution S-2222 (CHROMOGENIX) was added, and the change in absorbance at 405 nm was measured using SpectraMax 340PC384 (Molecular Devices). A calibration curve was prepared from the change in absorbance by human FXa (Enzyme Research Laboratories) at known concentrations, and the FXa production-promoting activity of the bispecific antibody was evaluated.
- ROTEM measurements were performed according to a usual method using the ROTEM delta measurement device (Tem International GmbH). As a Ca trigger, a calcium solution star-tem reagent (Ref No. 503-01, Tem International GmbH) was used.
- Thrombocheck APTT-SLA (Sysmex) was used as the APTT reagent. 50 μL of the APTT reagent was added to 50 μL of FIX disorder patient-derived plasma or FIX-deficient human plasma containing ACE910 and/or anti-FIX-Gla antibody (Thromb Res 2000; 100: 73-79). After incubation at 37° C. for five minutes, 50 μL of 0.02. mol/L calcium chloride solution was added to initiate the coagulation reaction, and APTT was measured according to a conventional method with an automated blood coagulation measurement device (CS-2000i, Svsmex).
- Using samples prepared by adding ACE910 to blood derived from patients with FIX disorder, percentage shortening of blood coagulation (initiation) time [(1—coagulation (initiation) time after addition of ACE910/coagulation (initiation) time before addition of ACE910)×100] according to Ca-triggered ROTEM was determined. Blood coagulation (initiation) time according to ROTEM was calculated as the sum of clotting time (CT) and clot formation time (CFT) measured by the ROTEM delta measurement device.
- Ca-triggered ROTEM was performed using 25 blood samples derived from 17 cases of FIX disorder patients under regular administration therapy with an FIX formulation (median FIX:C of 1.9 IU/dL; and FIX:C range of less than 0.2 IU/dL to 16.5 IU/dL). As a result, the coagulation (initiation) time was shortened in most cases by ex vivo addition of ACE910 (50 μg/mL), with a median percentage shortening of 18% (
FIG. 1 shows the ratios of blood coagulation (initiation) time for some of the samples). - Percentage shortening of APTT [(1—APTT after addition of ACE910/APTT before addition of ACE910)×100] was determined using samples prepared by adding ACE910 to plasma derived from FIX disorder patients or FIX-deficient human plasma.
- When ACE910 (100 μg/mL) was added ex vivo in the plasma of 10 cases of FIX disorder patients, no APTT shortening effect was observed in one FIX inhibitor-positive case, with a shortening ratio of −6% (APTT ratio of 1.06). However, in all of the remaining nine cases (FIX:C range of 0.9 IU/dL to 6.4 IU/dL). ACE910 was effective in shortening APTT, with a median shortening ratio of 39% (ranging from 35% to 45%) (APTT' ratio of 0.55 to 0.65) (
FIG. 2 ). - FIX formulation (BeneFix, Pfizer) was added at concentrations of 0, 0.01, 0.1, 1, 10, and 100 IU/dL to commercially-available FIX-deficient human plasma, and ACE910 was further added ex viva. The percentage by which the APTT was shortened after addition of 100 μg/mL
- ACE910 was evaluated. The result showed that the percentage APTT shortening was 7%, 11%, 19%, 26%, 30%, and 33% according to the respective concentrations of the FIX formulation (
FIG. 3-1 ). The APTT shortening effect of ACE910 was FIX concentration-dependent, and when the FIX concentration was from 1 IU/dL to 100 IU/dL, the level of change in the shortening ratio was nearly stable (26% to 33%). This effect was also slightly observed (shortening ratio of 7%) in FIX-deficient human plasma to which the FIX formulation was not added, but further addition of an anti-FIX-Gla antibody (anti-FIX Ab: prepared by referring to Thromb Res 2000; 100: 73-79) to this plasma ex viva (anti-FIX-Gla antibody: 150 μg/mL) cancelled this effect (shortening ratio of −3%) (FIG. 3-2 ). For the ACE910-added groups, 100 μg/mL ACE910 was added. Therefore, it was shown that FIX is essential for ACE910 to express its effect, and the effect is exerted in the presence of even a trace amount of FIX (at the level of 0.01 IU/dL). A calibration curve for APTT shortening by changes in the concentration of FIX was prepared by adding only the FIX formulation at varying concentrations to FIX-deficient human plasma, and this calibration curve was used to convert the APTT obtained with addition of ACE910 into FIX:C. As a result, the maximum effect of ACE910 in the presence of 0.1 IU/dL, 1 IU/dL and 10 IU/dL of FIX was equivalent to 0.6 IU/dL, 11 IU/dL, and 114 IU/dL of FIX:C (i.e., %), respectively. Thus, the effect of the FIX formulation was enhanced six to eleven times. Many severe hemophilia B cases have a little FIX activity of less than 1.0 IU/dL. This result suggested that ACE910 can be applied to hemophilia B patients with a very small amount of FIX. - The present invention provides methods of using multispecific antigen-binding molecules that functionally substitute for FVIII as a prevention method and/or a treatment method for onset and/or progress of bleeding, diseases accompanying bleeding, or diseases caused by bleeding in FIX disorders other than hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C. It is considered that multispecific antigen-binding molecules that functionally substitute for FVIII can be used not only as prevention methods and/or treating methods for bleeding in hemophilia A, acquired hemophilia. A, von Willebrand disease, and hemophilia C which are caused by FVIII dysfunction, but also as prevention methods and/or treating methods for bleeding in other FIX disorders, because of its procoagulant activity. In current therapy of FIX disorders, the need of repeated intravenous administration of a FIX formulation leads to the problem of difficulty in securing vascular access, and is very burdensome to the patients and care givers particularly in pediatric cases. The antibodies which are multispecific antigen-binding molecules that functionally substitute for FVIII (as an example, ACE9101) have been developed as a formulation for subcutaneous administration, and are expected to reduce the burden of administration compared to FIX formulations which require repeated intravenous administration. Therefore, the present invention may be promising as a prophylactic agent and/or therapeutic agent for FIX disorders. Furthermore, combined use of a multispecific antigen-binding molecule that functionally substitutes for VIII and a FIX formulation can enhance the effect of the FIX formulation, and this may be promising as a combination therapy which shows stable hemostatic effects.
Claims (17)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-069714 | 2017-03-31 | ||
JP2017069714 | 2017-03-31 | ||
PCT/JP2018/013547 WO2018181870A1 (en) | 2017-03-31 | 2018-03-30 | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/013547 A-371-Of-International WO2018181870A1 (en) | 2017-03-31 | 2018-03-30 | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/472,949 Continuation US20240052059A1 (en) | 2017-03-31 | 2023-09-22 | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210107994A1 true US20210107994A1 (en) | 2021-04-15 |
Family
ID=63677626
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/496,089 Abandoned US20210107994A1 (en) | 2017-03-31 | 2018-03-30 | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
US18/472,949 Pending US20240052059A1 (en) | 2017-03-31 | 2023-09-22 | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/472,949 Pending US20240052059A1 (en) | 2017-03-31 | 2023-09-22 | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii |
Country Status (7)
Country | Link |
---|---|
US (2) | US20210107994A1 (en) |
EP (1) | EP3603670A4 (en) |
JP (1) | JP7209298B2 (en) |
KR (1) | KR20190133230A (en) |
CN (1) | CN110461358A (en) |
TW (1) | TW201836636A (en) |
WO (1) | WO2018181870A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11214623B2 (en) | 2014-09-26 | 2022-01-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII) |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
US11612562B2 (en) | 2010-01-20 | 2023-03-28 | Chugai Seiyaku Kabushiki Kaisha | Solution preparation containing stabilized antibody |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101198698B (en) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | Process for production of polypeptide by regulation of assembly |
EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
KR102441231B1 (en) | 2013-09-27 | 2022-09-06 | 추가이 세이야쿠 가부시키가이샤 | Method for producing polypeptide heteromultimer |
TWI701435B (en) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | Method to determine the reactivity of FVIII |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
AR113142A1 (en) | 2017-09-29 | 2020-01-29 | Chugai Pharmaceutical Co Ltd | MULTISPECIFIC ANTIGEN BINDING MOLECULES THAT HAVE SUBSTITUTION ACTIVITY FOR THE COFACTOR FUNCTION OF BLOOD COAGULATION FACTOR VIII (FVIII), AND PHARMACEUTICAL FORMULATIONS CONTAINING SUCH ACTIVE MOLECULE AS INGREDIENT |
CN113368098B (en) * | 2020-03-10 | 2024-03-29 | 鲁南制药集团股份有限公司 | Application of icariin in preparation of medicine for preventing and treating hemophilia |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2584443B2 (en) | 1985-04-22 | 1997-02-26 | ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド | High-yield production of activated I-X-factor |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
FR2707189B1 (en) | 1993-07-09 | 1995-10-13 | Gradient Ass | Method for treating combustion residues and installation for implementing said method. |
EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
ATE390933T1 (en) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
DK1069185T3 (en) | 1998-04-03 | 2011-06-27 | Chugai Pharmaceutical Co Ltd | Humanized antibody to human tissue factor (TF) and method of constructing humanized antibody |
EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
DK1399484T3 (en) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Double-specific ligand and its use |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
CN101198698B (en) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | Process for production of polypeptide by regulation of assembly |
US20100003254A1 (en) | 2005-04-08 | 2010-01-07 | Chugai Seiyaku Kabushiki Kaisha | Antibody Substituting for Function of Blood Coagulation Factor VIII |
US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
TWI505838B (en) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody |
WO2012067176A1 (en) * | 2010-11-17 | 2012-05-24 | 中外製薬株式会社 | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
TW201625299A (en) * | 2014-06-20 | 2016-07-16 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii |
TWI700300B (en) * | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII) |
MX2017010734A (en) | 2015-04-17 | 2017-12-04 | Hoffmann La Roche | Combination therapy with coagulation factors and multispecific antibodies. |
JP2018123055A (en) | 2015-04-24 | 2018-08-09 | 公立大学法人奈良県立医科大学 | Pharmaceutical composition for use in prevention and/or treatment of blood coagulation factor xi (fxi) abnormalities comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii (fviii) |
-
2018
- 2018-03-30 JP JP2019510225A patent/JP7209298B2/en active Active
- 2018-03-30 EP EP18776553.2A patent/EP3603670A4/en active Pending
- 2018-03-30 KR KR1020197031876A patent/KR20190133230A/en not_active Application Discontinuation
- 2018-03-30 US US16/496,089 patent/US20210107994A1/en not_active Abandoned
- 2018-03-30 CN CN201880019962.8A patent/CN110461358A/en active Pending
- 2018-03-30 TW TW107111239A patent/TW201836636A/en unknown
- 2018-03-30 WO PCT/JP2018/013547 patent/WO2018181870A1/en unknown
-
2023
- 2023-09-22 US US18/472,949 patent/US20240052059A1/en active Pending
Non-Patent Citations (2)
Title |
---|
Kitazawa, Takehisa et al. Thrombosis and haemostasis vol. 117,7 (2017): 1348-1357. doi:10.1160/TH17-01-0030 (Year: 2017) * |
Rallapalli, P M et al. Journal of thrombosis and haemostasis :JTH vol. 11,7 (2013): 1329-40. doi:10.1111/jth.12276 (Year: 2013) * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11612562B2 (en) | 2010-01-20 | 2023-03-28 | Chugai Seiyaku Kabushiki Kaisha | Solution preparation containing stabilized antibody |
US11214623B2 (en) | 2014-09-26 | 2022-01-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII) |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
Also Published As
Publication number | Publication date |
---|---|
CN110461358A (en) | 2019-11-15 |
TW201836636A (en) | 2018-10-16 |
JP7209298B2 (en) | 2023-01-20 |
JPWO2018181870A1 (en) | 2020-02-06 |
EP3603670A4 (en) | 2021-03-10 |
EP3603670A1 (en) | 2020-02-05 |
KR20190133230A (en) | 2019-12-02 |
WO2018181870A1 (en) | 2018-10-04 |
US20240052059A1 (en) | 2024-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240052059A1 (en) | Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii | |
US20230212315A1 (en) | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii | |
WO2016171202A1 (en) | Pharmaceutical composition for use in prophylaxis and/or treatment of coagulation factor xi (fxi) disorders, comprising multispecific antigen binding molecule that substitutes for coagulation factor viii (fviii) function | |
WO2016047656A1 (en) | Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii) | |
WO2016047652A1 (en) | Method for measuring reactivity of fviii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA, JAPAN Free format text: ASSIGNOR HEREBY ASSIGNS TO ASSIGNEE A PARTIAL, UNDIVIDED RIGHT, TITLE, AND INTEREST;ASSIGNOR:PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY;REEL/FRAME:052860/0882 Effective date: 20200116 Owner name: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHIMA, MIDORI;NOGAMI, KEIJI;OGIWARA, KENICHI;SIGNING DATES FROM 20200106 TO 20200108;REEL/FRAME:051797/0071 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |